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Abstract
Modern living challenges female reproductive health. We are witnessing a rise in reproductive disorders and drop in birth 
rates across the world. The reasons for these manifestations are multifaceted and most likely include continuous exposure to 
an ever-increasing number of chemicals. The cause–effect relationships between chemical exposure and female reproductive 
disorders, however, have proven problematic to determine. This has made it difficult to assess the risks chemical exposures 
pose to a woman’s reproductive development and function. To address this challenge, this review uses the adverse outcome 
pathway (AOP) concept to summarize current knowledge about how chemical exposure can affect female reproductive 
health. We have a special focus on effects on the ovaries, since they are essential for lifelong reproductive health in women, 
being the source of both oocytes and several reproductive hormones, including sex steroids. The AOP framework is widely 
accepted as a new tool for toxicological safety assessment that enables better use of mechanistic knowledge for regulatory 
purposes. AOPs equip assessors and regulators with a pragmatic network of linear cause–effect relationships, enabling the 
use of a wider range of test method data in chemical risk assessment and regulation. Based on current knowledge, we propose 
ten putative AOPs relevant for female reproductive disorders that can be further elaborated and potentially be included in 
the AOPwiki. This effort is an important step towards better safeguarding the reproductive health of all girls and women.
Keywords Ovary · Reproduction · Adverse outcome pathway · AOP · Ovarian dysgenesis syndrome · ODS · Endocrine-
disrupting chemicals · EDC
Introduction
A woman’s reproductive health affects numerous aspects 
of her life, from the ability to conceive to personal well-
being and social standing. It is also of paramount importance 
for society more broadly, as it has direct consequences for 
overall birth rates, health of offspring, and national health 
budgets. Therefore, any factor that can negatively influence 
female reproductive development or function should be of 
utmost concern and efforts put in place to minimize poten-
tially harmful effects. In recent years, a growing body of 
evidence points towards an association between exposure 
to chemicals and female reproductive disorders, with cer-
tain life stages suggested to be particularly vulnerable to 
xenobiotic insult.
A current consensus is that many female reproductive 
disorders such as infertility (see Table 1 for definitions), 
polycystic ovary syndrome (PCOS), premature (or primary) 
ovarian insufficiency (POI), and early menopause have a 
common origin; disrupted ovarian development or function 
during development, collectively referred to as the ovarian 
dysgenesis syndrome (ODS) hypothesis (Buck Louis et al. 
2011; Johansson et al. 2017). This is analogous to other 
‘developmental origins of health and diseases (DOHaD)’ 
hypotheses, whereby disrupted tissue development or func-
tion can have long-lasting consequences for health and dis-
ease. It is easy to see how disrupted ovarian development 
can have lifelong consequences, since a fully functional 
 * Terje Svingen 
 tesv@food.dtu.dk
Extended author information available on the last page of the article
3360 Archives of Toxicology (2020) 94:3359–3379
1 3
reproductive system hinges on events occurring already 
during fetal life. It is more difficult, however, to determine 
causal relationships between disturbed development in early 
life and reproductive disorders later in life; especially in 
humans. This is due, not only, to the significant timespan 
between early initiating events and time of disease mani-
festations, but also to the sheer complexity of reproductive 
development, from the intrinsic regulatory aspects of genetic 
and hormonal control to the extrinsic influences posed by 
the environment.
Environmental factors are undoubtedly contributing to 
a rise in female reproductive disorders, likely also includ-
ing developmental exposure to industrial chemicals (Fowler 
et al. 2012; Hunt et al. 2016; Johansson et al. 2017). A clas-
sic example of an endocrine-disrupting chemical (EDC) 
causing female reproductive disease is the pharmaceutical 
diethylstilbestrol. Prescribed to women to alleviate preg-
nancy complications in the 1940–1970s, intrauterine expo-
sure to diethylstilbestrol turned out to have the disastrous 
consequence of causing vaginal cancers in daughters once 
they reached young adulthood (Reed and Fenton 2013). Fol-
lowing the discovery that fetal exposure to diethylstilbestrol 
could also cause additional female reproductive disorders 
in adulthood, there has been a multitude of reproductive 
disorders associated with fetal exposure to chemicals more 
broadly. This includes compromised fecundity (Table 1) 
after exposure to diethylstilbestrol (Palmer et al. 2001) or 
cigarette smoke (Jensen et al. 2006), PCOS after exposure 
to bisphenol A (Palioura and Diamanti-Kandarakis 2015), 
POI after exposure to perfluoroalkyl substances (Zhang et al. 
2018), premature menopause after exposure to diethylstil-
bestrol (Hatch et al. 2006), and more as discussed later in 
this review.
According to a recent estimate, as many as 330,000 chem-
icals are, or have been, in commerce (Wang et al. 2020). 
Because of the growing body of evidence suggesting that 
chemical exposures can disrupt female reproductive health, 
there is a clear need to better protect women, not least the 
unborn child, against harmful chemicals. With this comes a 
growing requirement to construct a better chemical testing 
strategy that can detect compounds of concern at an early 
stage of substance evaluation, ideally before they are intro-
duced onto the market. One such strategy can be based on 
the adverse outcome pathway (AOP) framework, used as a 
pragmatic tool to inform chemical safety assessment strate-
gies, as described in organization for economic co-operation 
and development (OECD) guidance document 184 (OECD 
2017).
In this review, we will use the AOP concept to highlight 
current knowledge and key knowledge gaps pertaining to 
several female reproductive disorders. This will guide our 
efforts to elaborate new and improved test strategies for the 
detection of chemicals disrupting female reproductive devel-
opment and function. First, we will provide an overview of 
female reproductive pathologies related to ovary function 
to define the scope of our work. In the second half of this 
review, we propose ten putative AOPs (pAOP) relevant for 
female reproductive disease outcomes, including scientific 
rationale for the various pAOPs. This work is an important 
first step in the EU Horizon 2020 project FREIA: A human 
evidence-based screening and identification approach for 
female reproductive toxicity of endocrine-disrupting chemi-
cals [(van Duursen et al. 2020); https ://www.freia proje ct.eu]. 
To maintain a close focus in the current review, we will 
address pAOPs related to disrupted pubertal onset, another 
component in the establishment of fertility in women, in a 
separate publication.
Ovarian pathologies
Most women who suffer from ovarian disorders will also 
be burdened with fertility issues. This does not mean that 
all subfertile women also suffer from ovarian dysgenesis, 
but we may speculate that many do, a view that is increas-
ingly substantiated by research (Axmon et al. 2000; Buck 
Louis et al. 2012; Ehrlich et al. 2012; Pizzorno 2018). If 
many ovarian dysgenesis cases arise from developmental 
exposure to industrial chemicals, the burden to our health 
costs becomes sizeable. Although they vary between studies, 
Table 1  Definition of terms related to female reproductive medicine
The terms used to denote female reproductive capacity and disorders are somewhat ambiguous and a general consensus does not exist (Habbema 
et al. 2004; Jenkins et al. 2004; Vander Borght and Wyns 2018). To avoid confusion, for the purposes of this review the following terms are 
defined as follows
Term Definition
Fertility Refers to actual output of reproduction. That is, the actual number of children born to a woman
Fecundity Refers to the capacity to conceive given unprotected intercourse
Subfertility Reduced fertility, i.e., still possible to conceive, but takes longer than average despite regular unprotected 
sexual intercourse
Infertility The failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse
Sterility A physiological inability to achieve pregnancy
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prevalence figures for infertility are high. A Dutch study 
found a prevalence of 2.2% between 1985 and 2006 when 
defining infertility as an inability to conceive for 2 years 
(van de Lisdonk et al. 2008). A study modelling worldwide 
infertility trends between 1990–2010 using data from 277 
surveys from 190 countries, on the other hand, reported a 
prevalence of 1.9% for primary infertility, defined as the 
inability to conceive a first child defined as ‘no live births 
for at least 5 years without the use of contraception (Mas-
carenhas et al. 2012).
Several ovarian disorders may first manifest after puberty, 
particularly if they have clinical signs related to the men-
strual cycle. The most common disorders diagnosed in 
young women of reproductive age are PCOS, ovarian cysts 
and endometriosis. PCOS is a collection of disorders and is 
characterized by biological or clinical hyperandrogenism, 
oligo- or anovulation, and the presence of an excess number 
of ovarian cysts. These cysts are actually immature follicles, 
each trapping an egg (Ibáñez et al. 2017). This accumulation 
of follicles will typically reduce the number of eggs avail-
able to be released from the ovaries (oligo-ovulation and 
anovulation) and affected women may experience irregu-
lar menses. The prevalence of PCOS varies depending on 
the diagnostic criteria used and the populations sampled. A 
2016 meta-analysis of studies grouped based on diagnostic 
guidelines (by NIH, Rotterdam, or The Androgen Excess-
PCOS Society) reported a prevalence of 6–10% of women 
(Bozdag et al. 2016). Androgen excess is a key characteristic 
of PCOS and observed in 60–80% of patients, but there are 
also other diagnostic criteria such as anovulation or ultra-
sound confirmation of polycystic ovarian morphology (Gol-
drat and Delbaere 2018; Ibáñez et al. 2017). Though the 
etiology of PCOS remains unclear, it has been suggested that 
overexposure to androgens in utero may increase the risk for 
developing PCOS later in life (Filippou and Homburg 2017). 
Although human studies on prenatal exposure to EDCs and 
PCOS are lacking, there are some studies that have com-
pared levels of EDCs in PCOS patients. A meta-analysis of 
11 case–control studies reported that women with PCOS had 
higher levels of bisphenol A compared to controls without 
PCOS (Hu et al. 2018). Similar results were found for levels 
of perfluorooctanoic acid and perfluoro-octanesulfonate in 
PCOS patients (Vagi et al. 2014).
Endometriosis is a non-malignant condition, whereby 
tissue normally lining the uterine cavity also grows on the 
outer surface of the uterus, and even on the ovaries and 
elsewhere in the peritoneal cavity (Vercellini et al. 2014). 
It may cause the formation of cysts known as endometrio-
mas, a painful condition associated with an increased risk 
for infertility (Eisenberg et al. 2018; Prescott et al. 2016). 
Prevalence rates of endometriosis vary greatly between stud-
ies, but, in the general population, it is estimated to affect 
around 0.7–8.6% of women. Strikingly, the prevalence of 
endometriosis is up to 70% among infertile women (Ghi-
asi et al. 2020). There is no consensus on the etiology of 
endometriosis, but it is considered an estrogen-dependent 
disease (Kitawaki et al. 2002), thus endocrine disruptors 
are regarded as potential causal factors (Crain et al. 2008). 
This is also why we include endometriosis under ‘ovarian 
dysgenesis disorders’, as it may arise from early disruption 
to ovary development. For example, prenatal exposure to 
diethylstilbestrol leads to an 80% increased risk of develop-
ing endometriosis in women from the National Health and 
Nutrition Examination Survey (NHANES II) cohort who 
had not previously been diagnosed with infertility or can-
cer (Missmer et al. 2004). In addition, associations between 
endometriosis and various chemicals have been observed in 
case–control studies, including polychlorinated biphenyls, 
polybrominated diphenyl ethers, and various organochlorine 
pesticides (Ploteau et al. 2017; Upson et al. 2013).
Other indications of ovarian dysfunction may first 
become apparent in adulthood, when women wish to con-
ceive. These include infertility and POI. A woman is con-
sidered to have POI if she is under 40 years of age, has 
had amenorrhea (absence of menstrual bleeding) for more 
than 4 months and two elevated serum follicle-stimulating 
hormone (FSH) measurements within the menopausal range 
occurring at least 1 month apart (Nelson 2009). There are 
multiple established etiologies, but over 90% of POI cases 
are idiopathic without any obvious cause (Nelson 2009; 
Torrealday et al. 2017). Women with POI may experience 
symptoms similar to menopause as a result of low estro-
gen levels. Unlike postmenopausal women, however, they 
may still become pregnant, albeit with a reduced chance 
of conceiving (Fraison et al. 2019). The prevalence of POI 
is generally estimated to be 1%, but a study using Swedish 
Patient Registry data from 1973 to 1993, including just over 
1 million women, reported a prevalence of 1.9% (Lagergren 
et al. 2018). Furthermore, based on a recent meta-analysis of 
31 studies, a pooled prevalence of 3.7% was found (Golezar 
et al. 2019). A few studies report on associations between 
chemical exposure levels and POI. Exposure to perfluori-
nated alkyl substances was associated with a higher risk 
for POI in Chinese women (Zhang et al. 2018), whereas a 
cross-sectional study on women from the USA looking at 
over 100 EDCs found associations between early menopause 
and numerous compounds, including phthalates, polychlo-
rinated biphenyls and organochlorine pesticides (Grindler 
et al. 2015). Finally, tobacco smoke has been shown by sev-
eral studies to correlate negatively with both POI and early 
menopause, as reviewed by others (Vabre et al. 2017).
It is clear from the above-mentioned literature that female 
reproductive health is challenged by developmental expo-
sure to chemicals. This view is further substantiated by a 
large number of animal studies, as will be discussed later. 
The challenge is that, despite clear associations between 
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exposure and disease manifestations, we lack essential fun-
damental knowledge at the more mechanistic level about 
how these diseases develop and how chemical stressors can 
initiate disease development. This is exactly the type of 
information we need if we are to more rapidly, and with bet-
ter precision, screen a large number of potentially harmful 
chemicals and thereby regulate their use before they cause 
health problems. One vision is to amass enough mechanistic 
knowledge that we can elaborate into robust safety testing 
strategies making use of both animal and non-animal data 
when testing chemicals. One strategy to achieve this is by 
the structured gathering of our knowledge using the AOP 
framework and identifying needs for test method develop-
ment. This is the incentive for the work presented in this 
review. In the following, we will briefly introduce the AOP 
concept before continuing with elaborating a number of 
putative AOPs (pAOP). We believe that these pAOPs are a 
good starting point for further development aimed at assist-
ing chemical risk assessment and regulation.
The adverse outcome pathway (AOP) 
concept in brief
An AOP describes a sequence of events from an initial 
molecular ‘trigger’ through to an adverse outcome (AO) in 
an intact organism. An AOP does not aim to cover all events 
that take place in a complex biological system challenged 
by a chemical, nor all the steps towards an adverse effect, 
but rather focusses on a minimum number of key events 
(KEs) that can help explain cause–effect relationships and 
at the same time be measurable. Central to the AOP thinking 
is that the AOs should be of relevance for chemical safety 
assessment or regulatory purposes (Ankley and Edwards 
2018). To enable the scientific community to share, develop 
and discuss their AOP-related knowledge, the OECD has 
launched the "Adverse Outcome Pathway Knowledge Base 
(AOP-KB)", which includes the AOPwiki platform, where 
AOPs can be entered and information about links between 
MIEs, KEs, and AOs presented (https ://aopkb .oecd.org/
backg round .html).
As described in the OECD User Handbook (OECD 
2018b), a typical AOP (see Table 2 for key component defi-
nitions) starts with a molecular initiating event (MIE), which 
describes the first chemical interaction with a biomolecule. 
This MIE, or ‘trigger’, then leads to a downstream KE: 
defined as a change in biological or physiological state that 
is both measurable and essential to the progression towards 
a specific AO. The AO is in itself a KE, but of regulatory 
significance and typically describes an apical endpoint: an 
observable effect in an intact organism, such as a clinical 
or pathological sign, that is indicative of a disease state 
resulting from exposure to a toxicant (Krewski et al. 2010). 
Finally, the individual KEs in an AOP should be linked by 
key event relationships (KERs), which refer to biologically 
plausible and predictive relationships between two KEs.
Once an AO has been defined, and specific plausible 
causative KEs identified, this information is organized into 
linear cause–effect relationships, or pathways, as exempli-
fied in Fig. 1: AOP7, from the AOPwiki, which describes a 
relationship between reduced aromatase levels with irregu-
lar ovarian cycling and impaired fertility (Nepelska et al. 
2016). This, of course, is a simplified view of what is taking 
place in real life, yet serves its purpose well by highlight-
ing KEs that can be measured by different tests, whether 
in silico, in vitro or in vivo. An AOP can also be branched 
should two or more KEs be essential for the progression to a 
downstream event, or if one KE leads to two or more down-
stream events. Likewise, individual KEs would necessarily 
be shared by many different AOs across biological systems 
and can thus serve as anchor points to create AOP networks. 
Examples of this can be seen in Figs. 2, 3, 4, 5 and 6.
It is important to note that AOPs are not specific to, or 
defined by, any specific chemical, but rather represents a 
biologically plausible chain of events that can be triggered 
by chemical exposure (Ankley and Edwards 2018). In this 
Table 2  Definition of terms used to describe an adverse outcome pathway (AOP); adapted from (OECD 2018b)
Term Abbreviation Definition
Molecular initiating event MIE The initial point of interaction between a chemical/stressor and a biomolecule within an organism that 
will result in a disruption capable of initiating the AOP
Key event KE A change in biological or physiological state that is both measurable and necessary to progress 
through the AOP
Key event relationship KER A biologically plausible and scientifically based relationship between two KEs, describing a causal 
and predictive connection between events that can facilitate extrapolation of the state of a down-
stream event from known (measured or predicted) upstream events
Adverse outcome AO A KE describing a change to a biological or physiological state that is generally regarded of regula-
tory significance or equivalent to an apical endpoint in an accepted regulatory guideline toxicity test
Apical endpoint An observable effect in an intact organism, such as a clinical or pathological sign, that is indicative of 
a disease state resulting from exposure to a toxicant. In essence, this is an AO
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Aromatase (Cyp19a1) reduction leading to impaired fertility in adult females
Molecular Cellular/Tissue Organ Organism
AO
P 
7 reduced E2 
synthesis
ovarian cycle 
irregularity
impaired 
fertility
reduced
aromatase 
levels
reduced 
circulating E2
PPAR
activation
Fig. 1  AOP7 from the AOPwiki describing PPARγ-mediated reduc-
tion in aromatase as a MIE leading to irregular ovarian cycling and 
impaired fertility in adult females. Activation of the peroxisome pro-
liferator activated receptor gamma (PPARγ) can impair steroidogene-
sis via reduced aromatase level (expression or activity), which causes 
reduced circulating estradiol (E2) levels. This will ultimately affect 
ovarian cycling and fertility. The AOP is mainly based on rodent 
data, with supporting evidence from human epidemiological studies. 
Adapted from the AOPwiki at https ://aopwi ki.org/aops/7
pAOP network: “Disrupted meiosis leading to impaired fertility”
Molecular Cellular/Tissue Organ Organism
impaired 
GPER activity
?
disrupted 
cAMP and 
cGMP levels
impaired     
syn. complex 
assembly
disrupted 
synapsis/ 
recombination
oocyte 
aneuploidy
pA
O
P 
1
pA
O
P 
2
pA
O
P 
3
disrupted 
meiosis
reduced  
follicle pool
impaired 
fertilityreduced RA germ cell loss
CYP26B1 
expression
impaired 
oocyte quality
Fig. 2  Putative AOP (pAOP) network for perturbed meiosis leading 
to impaired fertility in females. pAOP 1: germ cell meiosis in females 
initiates during fetal life in humans. Retinoic acid is a critical factor 
initiating meiosis in the fetal ovaries. Ectopic activation, or main-
tained expression, is hypothesized to prevent retinoic acid-dependent 
activation in the ovaries. pAOP 2: initiation and maintenance of mei-
otic arrest requires high levels of cAMP mediated through G-protein-
coupled receptors (GPCRs) such as GPER. By blocking, e.g., GPER, 
meiosis can be disrupted by affecting cAMP/cGMP levels. pAOP 3: 
the proper assembly of the synaptonemal (syn.) complex is necessary 
for meiosis, a process that can be disrupted by chemical exposures. 
The molecular triggers are yet to be characterized
pAOP network: “Ectopic estradiol/AHR activation leading to impaired fertility”
Molecular Cellular/Tissue Organ Organism
impaired 
fertility
pA
O
P 
4 accelerated 
follicle 
formation
reduced  
follicle pool
increased
E2 signaling
AHR 
activatiion
compromised 
ovarian 
reserve
increased 
NR2F1 
activation
dysregulated 
CYP11A1 
activity
pA
O
P 
5
?
Fig. 3  Putative AOP (pAOP) network for disrupted follicle formation 
leading to impaired fertility in females. Follicle assembly is essential 
for adult fertility and depends on a coordinated sequence of cell pro-
liferation and differentiation, collection of primordial granulosa cells 
around germ cells in meiotic arrest, as well as germ cell death. pAOP 
4: aryl hydrocarbon receptor (AHR) and estrogen receptor α (ERα) 
signaling are known to be involved in regulating these processes. 
AHR activation can also activate other downstream effects, for exam-
ple as proposed in pAOP 5 (Fig. 4). The AOP is based primarily on 
human fetal ovary studies, supported by animal, experimental and 
human epidemiological studies
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pAOP network: “Disrupted folliculogenesis leading to impaired fertility”
Molecular Cellular/Tissue Organ Organism
pA
O
P 
5
impaired 
fertility
pA
O
P 
6
reduced  
follicle pool
increased 
apoptosis
increased
pro-apoptotic
protein
expression
AHR           
activation
resting 
primordial 
follicle growth
primordial 
follicle 
activation
PI3K           
activation
premature 
ovarian 
insufficiency
Fig. 4  Putative AOP (pAOP) network for disrupted folliculogenesis 
leading to impaired fertility in females. Folliculogenesis is a complex 
process regulated by several signaling pathways. As suggested, the 
disruption to key signaling molecules such as pAOP 5 AHR or pAOP 
6 PI3K can affect the ovarian follicles by separate cellular events, 
ultimately reducing the availability of competent follicles. In turn, 
this can affect female physiology and fertility
pAOP network: “Disrupted follicle maturation leading to impaired fertility”
Molecular Cellular/Tissue Organ Organism
pA
O
P 
7 reduced 
estradiol 
synthesis
ovarian cycle 
irregularity
impaired 
fertility
reduced 
circulating E2
Aromatase 
inhibition
impaired 
oocyte 
maturation
modified 
LH/FSH 
release
reduced 
GDF9 
expression
reduced
INSL3
 levelspA
O
P 
8
reduced 
CYP17A1 
expression
reduced 
androstene-  
dione levels 
?
Fig. 5  Putative AOP (pAOP) network for impaired steroidogenesis/
follicle maturation leading to impaired fertility in females. Steroido-
genesis is intimately linked to reproductive function and disrupted 
steroid synthesis or action can impair fertility by many different 
mechanisms. pAOP 7: aromatase (CYP19A1) action is highlighted as 
being central to female reproduction, as enzymatic activity is neces-
sary for estrogen (estradiol) synthesis, which in turn is central for the 
regulation of oocyte maturation, but also ovarian cyclicity. pAOP 8: 
insulin-like factor 3 (INSL3), another hormone synthesized by theca 
cells, is also important for oocyte maturation, with knockout mice 
displaying an infertility phenotype or increased follicle apoptosis. The 
upstream MIE remains elusive and could also include compromised 
theca cell differentiation or function
pAOP network: “Disrupted folliculogenesis leading to impaired fertility”
Molecular Cellular/Tissue Organ Organism
pA
O
P 
10 mature    
oocyte atresia
ovarian cycle 
irregularity
impaired 
fertility
decreased
LHCGR 
expression
disrupted 
LHCGR 
methylation
pA
O
P 
9 impaired 
follicle 
recruitment
reduced  
ovulation
AR
inhibition
reduced      
AR signalling
Fig. 6  Putative AOP (pAOP) network for disrupted folliculogenesis 
leading to impaired fertility in adult females. Similarly to pAOPs 5, 6 
(Fig. 4), folliculogenesis can be disrupted through many different key 
signaling pathways. In adult females, this includes pAOP 9 AR and 
pAOP 10 LHCGR, which, upon disruption, could negatively impact 
follicle recruitment or maturation, ultimately causing irregular ovar-
ian cycling and subfertility
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review, we will define a set of AOs for female reproductive 
health that we consider relevant to include in a test guideline, 
even though they may not yet be included as apical endpoints 
in any existing regulatory toxicity testing guideline. We will 
use these AOs as signposts for describing current knowledge 
about causal relationships between chemical exposures and 
female reproductive diseases.
To structure the AOPs into an accessible framework, 
we have opted to define key processes that are relevant for 
female reproductive disorders as starting points. We delib-
erately refer to all AOPs in this review as ‘putative’, as they 
are working concepts not yet included in the AOPwiki. This 
means that the numbering of pAOPs in this review are not to 
be confused with the numbering in the AOPwiki. From the 
processes considered crucial for ovarian and oocyte devel-
opment such as meiosis, follicle assembly, folliculogenesis 
and atresia, we have defined putative AOs that could mani-
fest from developmental disruption by chemical exposures. 
Our long-term goal is to build more complete toxicological 
safety assessments focused on female reproductive health 
and based on biological knowledge. These (p)AOPs can be 
used to confirm the utility of available test assays or prompt 
the development of new assays.
Adverse outcome pathways as they relate 
to key processes in ovarian development 
and function
Ovarian development starts early in fetal life. It involves 
many essential processes, all of which can be disrupted and 
cause reproductive problems later in life. These essential 
processes include extra-gonadal specification of primor-
dial germ cells, their migration to, and colonization of, the 
ovaries, and initiation of meiosis, alongside differentiation 
of organization of ovarian somatic cells and their niches. 
In some instances, chemicals can be triggers that disrupt 
these events and cause reproductive disorders that often 
manifest much later in life. Similarly, chemical exposures 
during adulthood can affect ovarian function or worsen the 
effects of developmental exposures. In the following, we 
propose ten pAOPs related to female reproductive disorders, 
originating from the disruption of fundamental processes in 
ovarian development or function.
Adverse outcome pathways involving meiosis
Meiotic division is unique to germ cells and involves one 
round of DNA replication followed by two successive cell 
divisions—first the separation of homologous chromosomes 
(meiosis I), and then sister chromatids (meiosis II)—to yield 
haploid eggs or sperm. Meiosis initiates at 11–12 weeks of 
gestation in humans (Hunt and Hassold 2008), whereas it 
starts around 13 day post coitum (dpc) in mice (McLaren 
and Southee 1997). During fetal life, meiosis proceeds 
through the prophase I events synapsis and recombination, 
but is arrested in meiosis I until ovulation (Laisk et al. 2019). 
FSH and luteinizing hormone (LH) secreted by the pituitary 
from puberty onwards trigger exit from prophase I arrest, 
and primary oocytes complete the first meiotic division prior 
to ovulation, which will be discussed later. Here, we will 
focus on perturbed meiotic entry and progression in the fetal 
ovary as well as maintenance of meiotic arrest, as shown in 
the pAOP network, as presented in Fig. 2.
pAOP‑1: “reduced retinoic acid levels lead to reduced 
follicle pool and impaired fertility in females”
This pAOP proposes that reduced retinoic acid levels will 
prevent oocytes from entering meiotic prophase I during 
early ovarian development. Ectopic activation of the retinoic 
acid-degrading enzyme CYP26B1 (Cytochrome P450 fam-
ily 26, subfamily B, member 1) is proposed as one potential 
mechanism by which this occur, but the central step remains 
reduced retinoic acid regardless of upstream molecular regu-
lation. Low or no retinoic acid in the ovaries will lead to 
a reduced number of primordial follicles and ultimately 
a diminished follicle pool. The rationale for including 
CYP26B1 as a MIE is that the enzyme is expressed in early 
stage ovaries prior to meiotic entry and CYP26B1 acts as 
the retinoic acid-degrading enzyme in the testes (Bowles 
et al. 2018). In other words, ectopic activation of CYP26B1 
in the fetal ovaries would mimic the testis milieu and the 
female (XX) germ cells would initiate a developmental 
trajectory otherwise reserved for germ cells located in the 
testes, i.e., germ cell sex reversal (Spiller et al. 2017). This 
is the opposite to what would take place in the testes in the 
presence of a xenobiotic blocking CYP26B1 function, as 
previously depicted in a pAOP for disrupted testis develop-
ment (Draskau et al. 2020).
Supporting evidence Retinoic acid initiates meiosis by 
inducing expression of Stra8 (Stimulated by retinoic acid 8), 
which subsequently triggers a chain of events required for 
meiotic progression; in mice (Bowles et al. 2006; Koubova 
et al. 2006) and in humans (Childs et al. 2011; Le Bouffant 
et al. 2010). Correct temporal retinoic acid-induced meiotic 
initiation thus seems crucial for the progression of oocyte 
development and ultimately a woman’s fertility (Bowles 
et al. 2006; Le Bouffant et al. 2010). Indeed, oocytes in vita-
min A-deficient rats fail to enter meiosis by not upregulating 
Stra8 (Li and Clagett-Dame 2009), showing an environmen-
tal vulnerability of the retinoid balance for germ cell devel-
opment. In mice, the retinoic acid metabolizing enzyme 
CYP26B1 is an important factor in retinoic acid balance. 
Cyp26b1 is expressed in both ovaries and testis until 12.5 
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dpc in mice, after which expression becomes testis spe-
cific. CYP26B1 is thought to be essential for degradation of 
retinoic acid and prevent meiotic entry of male germ cells 
(Bowles et al. 2006). Here, the proposal rests on the assump-
tion that perturbed gonadal differentiation can cause ectopic 
expression of CYP26B1 in ovaries at stages when retinoic 
acid is needed to induce meiotic entry in female germ cells.
CYP26B1 appears to be expressed more robustly in 
human fetal ovaries and not downregulated during germ 
cell entry into meiosis, as in mouse ovaries (Childs et al. 
2011; Frydman et al. 2017; Jørgensen et al. 2012), so the 
conserved role for this enzyme in germ cell development 
remains unclear. Germ cell differentiation in the human fetal 
ovary is asynchronous, with the presence of oogonia as late 
as second and third trimester (Frydman et al. 2017). This 
could indicate that CYP26B1 does have some meiotic inhib-
itory influence, or that, as suggested in above-mentioned 
studies, there are other factors, such as FGF9 (Fibroblast 
growth factor 9), involved in the sexually dimorphic ini-
tiation of meiosis versus mitotic arrest in male and female 
human gonads. Another explanation could be that the reti-
noic acid-synthesizing enzyme ALDH1A (Aldehyde dehy-
drogenase 1 family, member A1) is expressed in the ovary 
proper in humans, but in the adjacent mesonephros in mice. 
Thus, human ovaries have an intrinsic capacity to synthesize 
retinoic acid, which could trigger meiotic initiation at local 
sites within the ovary, as opposed to the anterior-to-poste-
rior wave resulting from retinoic acid entering the gonads 
from the mesonephros at the anterior pole in mouse ovaries 
(Bowles et al. 2006; Childs et al. 2011).
Evidence for  chemical triggers In mice, in utero exposure 
to bisphenol A can result in reduced expression of Stra8 at 
17.5 dpc (Lawson et al. 2011). Exposure to di(2-ethylhexyl) 
phthalate can reduce expression of Stra8 (gene and protein) 
at 13.5 dpc in mice (Zhang et  al. 2015). The mechanism 
behind the effects remains unknown.
pAOP‑2: “impaired GPER activity leads to reduced follicle 
pool and impaired fertility in females”
This pAOP proposes to link disrupted GPER (G-protein-
coupled Estrogen receptor 1) signaling during initiation 
(fetal life) and maintenance (postnatal and adult life) of mei-
otic arrest and reduced follicle pool. The initiation, as well 
as maintenance, of meiotic arrest at prophase I requires high 
levels of cAMP, which is mediated through (GPCR (G-pro-
tein-coupled receptors) such as GPER. Thus, by regulating 
cAMP accumulation in oocytes, GPER signaling indirectly 
controls primordial follicle assembly and oocyte matura-
tion (Pang and Thomas 2018). In the presence of estrogens, 
GPER signaling provides rapid non-genomic signaling. 
Thus, by disrupting estrogen-dependent GPER signaling, 
the follicle pool can be significantly reduced.
Supporting evidence Activation of GPER is essential for 
estradiol-mediated primordial follicle formation (Pepling 
2006; Wang et  al. 2008) and GPER activity can affect 
oocyte maturation in mammalian and non-mammalian ver-
tebrates (Li et al. 2013; Peyton and Thomas 2011). Reduced 
GPER activity during early stages of ovary development 
can reduce the size of the primordial follicle pool and thus 
affect the number of oocytes available at reproductive age. 
The maintenance of meiotic arrest in prophase I is mediated 
through GPCRs by activating adenylate cyclase to initiate 
the intracellular accumulation of cAMP and PKA (Protein 
kinase A) activation, ultimately inactivating the MPF (Mat-
uration promoting factor) (Sen and Caiazza 2013). The abil-
ity of GPER to inhibit oocyte maturation is evidenced by the 
fact that oocyte maturation can be reversed with the GPER 
antagonist catecholestrogen (2- hydroxyestradiol-17beta) 
(Chourasia et al. 2015).
Evidence for  chemical trigger GPER-mediated responses 
are sensitive to both estradiol and EDCs with estrogenic 
potential. For example, bisphenol A has a higher binding 
affinity to GPER than to nuclear ERs (Estrogen receptors)) 
(Thomas and Dong 2006). It is evident that bisphenol A can 
increase GPER activity in male reproductive organs (Sheng 
and Zhu 2011; Vom Saal and Hughes 2005). Bisphenol A 
can also promote proliferation of ER-negative breast cancer 
cells, which suggests a proliferative effect of bisphenol A via 
the GPER pathway (Dong et al. 2011). Atrazine, a pesticide 
with reported estrogenic potential, can promote prolifera-
tion of ovarian cancer cells via GPER-EGFR induced Erk 
(Extracellular signal-regulated kinase) phosphorylation and 
expression of estrogen target genes, which may also stimu-
late ovarian cancer cell migration (Albanito et al. 2015). So 
too, the biocide DDT (1,1,1-trichlor-2,2-bis(4-chlorphenyl)
ethan), or more precisely the p,p’ and o,p’ isomers of DDT 
and DDE, can both bind to GPER (Thomas and Dong 2006). 
In utero exposure to DDT has been associated with longer 
time to pregnancy in women, but solid evidence for DDT or 
related compounds affecting female reproductive function 
via the GPER pathway remains elusive.
pAOP‑3: “disrupted meiotic division leads to impaired 
oocyte quality and impaired fertility in females”
This pAOP proposes to link disrupted synapsis and recom-
bination via incorrect assembly of the synaptonemal com-
plex with aneuploidy in oocytes and consequently reduced 
fertility in females. In humans, aneuploidy is found in ~ 20% 
of oocytes and the incidence increases with age. Approxi-
mately 35% of all miscarriages are aneuploid. Aneuploidy 
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is the leading genetic cause of developmental and mental 
disabilities in pregnancies that survives to term (Hassold 
et al. 2007; Hassold and Hunt 2001).
Supporting evidence Pairing of homologous chromo-
somes (synapsis) is mediated by the synaptonemal com-
plex. One of the most important proteins for its establish-
ment is SYCP3 (Synaptonemal complex protein-3). In Sycp3 
knockout mice, females are subfertile due to increased ane-
uploidy rates of oocytes (Yuan et al. 2002). The origin of 
aneuploidy in humans is complex, but the majority seems to 
occur already when the future mother of the child was her-
self a developing fetus. Typically, errors in the major events 
of prophase I—cohesion of sister chromatids, synapsis and 
recombination—can lead to incorrect chromosome segrega-
tion and pass this on to following generation (Hassold et al. 
2007; Hassold and Hunt 2001). Hence, disrupted assembly 
of the synaptonemal complex and thereby incorrect synap-
sis causes aneuploidy or cell death (Bolcun-Filas and Schi-
menti 2012; Yuan et al. 2002; Zickler and Kleckner 2015).
Evidence for chemical triggers In mice, exposure to bisphe-
nol A during the final stages of oocyte growth can increase 
the rate of aneuploidy (Hunt et al. 2003), evidenced by a high 
frequency of synaptic defects, increased levels of recombi-
nation, as well as increased frequency of aneuploid oocytes 
and fetuses in adult females (Susiarjo et al. 2007). In Rhe-
sus monkeys, significantly increased recombination is also 
seen in ooctyes after fetal exposure to bisphenol A, but only 
with a tendency towards synaptic defects (Hunt et al. 2012). 
Increased recombination has also been demonstrated in cul-
tured human fetal oocytes exposed to bisphenol A; however, 
cytotoxicity was also observed at the concentrations, where 
effects were observed (Brieño-Enríquez et  al. 2011). A 
recent study has also shown atrazine to disrupt meiosis and 
follicle formation in mice (Gely-Pernot et al. 2017).
Adverse outcome pathways involving primordial 
follicle assembly
Primordial follicles form in the ovary by follicle assembly, a 
process that involves breakdown of germ cell nests, death of 
germ cells, and intrusion of pre-granulosa cells between the 
germ cells. In humans, follicle assembly is chaotic-looking 
and completed during fetal life, whereas in rats and mice it is 
initiated during fetal life but completed, in a more organized 
process than the human, around 6 days after birth (Grive and 
Freiman 2015; Pepling et al. 2010). Regardless of temporal 
differences in follicle assembly, however, the processes that 
are involved appear to be shared between species (Grive 
and Freiman 2015). Thus, rodents remain useful models for 
characterizing the molecular mechanisms underpinning both 
normal and abnormal primordial follicle assembly, as shown 
in Fig. 3.
AOP‑4: “disrupted ESR and AHR signaling leads to disturbed 
primordial follicle formation and impaired fertility 
in females”
This pAOP network proposes that increased ERα and AHR 
(Aryl hydrocarbon receptor) signaling following EDC 
exposure results in accelerated primordial follicle forma-
tion and germ cell death, by dysregulating primordial fol-
licle formation and intraovarian signaling. Ultimately, this 
leads to impaired adult fertility via compromised ovarian 
reserve. AHR is a ligand-activated transcription factor that 
is expressed in mouse and human ovaries and well-known 
for its role in xenobiotic metabolism. This pAOP is based on 
the weight of evidence for fetal ovarian development in the 
human, including disruption following exposure to maternal 
smoking in utero (Fowler et al. 2014) and underpinned by 
data from studies of model species considered more similar 
to the human than rat or mouse in terms of ovarian devel-
opment, including baboon and hamster. The validity of the 
pAOP is supported by population-level evidence for the 
adverse effects of in utero exposure to maternal smoking 
on subsequent adult fertility of female human offspring (Ye 
et al. 2010).
Supporting evidence The sequence from maternal smoking 
to fetal AHR activation, disturbed primordial follicle forma-
tion and reduced germ cell proliferation are well established 
(Anderson et  al. 2015; Jurisicova et  al. 2007; Matikainen 
et al. 2001; Tuttle et al. 2009). The increased AHR signaling 
in smoke-exposed fetuses is likely due to increased estrogen 
and estrogenic polycyclic aromatic hydrocarbon metabolites 
(Fowler et al. 2014), which leads to increased AHR signal-
ing, (Tarnow et al. 2019). In addition, maternal smoking is 
associated with disturbed or reduced number of germ and 
gonadal somatic cells in the offspring (Lutterodt et al. 2009; 
Mamsen et  al. 2010). The consequence of early estradiol 
and AHR activation would thus be early onset of primordial 
follicle formation (premature increase in germ cell VASA 
protein (gene DDX4: DEAD-box helicase 4) when germ 
cell OCT4 protein predominates in control (gene POU5F1: 
POU class 5, homeobox 1) and, given imbalanced propor-
tions of germ and somatic cells, subsequently reduced pri-
mordial follicle pool establishment, leading to shorter repro-
ductive lifespan and, ultimately, reduced fertility.
Evidence for  chemical triggers In smoke-exposed human 
fetuses and its ovaries, increased AHR and estrogen signal-
ing has been associated with increased expression of steroid 
hormone receptor NR2F1 (Nuclear Receptor subfamily 2, 
group F, member 1), dysregulated CYP11A1 (Cytochrome 
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P450 family 11, subfamily A, member 1) and FSHR (with-
out alterations in circulating fetal FSH), increased NR2E1 
(Nuclear receptor subfamily 2, group E, member 1) and 
HRK (Activator of apoptosis harakiri), reduced NOBOX 
(Newborn ovary Homeobox-encoding gene) and reduced 
inhibin/activin ratio (Fowler et al. 2014).
Adverse outcome pathways involving 
folliculogenesis and follicular atresia
Folliculogenesis is the process by which activated primordial 
follicles grow and mature into competent oocytes in women 
of reproductive age, and involves several maturation stages 
(Gougeon 1986). Once activated, the surrounding granulosa 
cells proliferate to form a secondary follicle comprising two 
or more complete layers of granulosa cells. A liquid filled 
cavity, the antrum, will emerge within the granulosa cell lay-
ers to form an antral follicle that will continue to grow into a 
pre-ovulatory follicle. Once folliculogenesis has commenced 
it cannot be halted, nor reversed. The recruited follicle will 
either complete the maturation process or die by atresia. 
Folliculogenesis takes several menstrual, or estrus, cycles 
to complete. In humans it is estimated to take 6–9 months, 
whereas in mice, it takes at least 47 days (Gougeon 1986; 
Zheng et al. 2014).
Folliculogenesis comprises both a gonadotropin-inde-
pendent and a gonadotropin-dependent growth phase. The 
gonadotropin-independent phase covers follicle activation 
and growth up to small antral stages. These stages can be 
seen even before activation of the hypothalamic–pitui-
tary–gonadal axis during puberty (Abel et al. 2000). All 
follicles growing in the absence of gonadotropins, however, 
will eventually die by atresia. Conversely, small antral fol-
licles will be stimulated to grow by FSH secreted from the 
pituitary gland after puberty. Once they become tertiary/
Graafian follicles, they have reached a pre-ovulatory size, 
and a surge of LH will trigger final oocyte maturation, 
resumption of meiosis and subsequent ovulation.
Follicle growth is largely controlled by local autocrine 
and paracrine growth factors belonging to the TGFβ (Trans-
forming growth factor beta) superfamily that are secreted by 
granulosa cells and oocytes of activated follicles. For exam-
ple, activation of PI3K (Phosphoinositide 3-kinase) signal-
ing leads to secretion of GDF9 (Growth differentiation factor 
9) and BMP15 (Bone morphogenetic protein 15) from the 
oocytes, which in turn stimulate granulosa cell survival and 
proliferation through BMPR (Bone morphogenetic protein 
receptor)-mediated SMAD signaling. In addition, GDF9 is 
essential for mouse follicle development beyond primary 
stage (Dong et al. 1996). Granulosa cells secrete inhibins, 
activins and AMH (anti-Müllerian hormone), and AMH is 
involved in inhibition of the early stages of follicle growth 
(Carlsson et al. 2006; Durlinger et al. 2002; Visser et al. 
2006). Notably, blood levels of AMH is proportional to the 
number of ovarian follicles, thus being a useful biomarker 
for assessing the ovarian reserve in women (Broekmans 
et al. 2008).
From the secondary follicle stage, the oocyte is sur-
rounded by granulosa and theca cells. Theca cells produce 
androgens, which are transported to the granulosa cells and 
converted to estrogens by aromatase. Estrogens, in turn, 
stimulate a feedback loop that regulates androgen synthe-
sis in the theca cells. This interplay between granulosa and 
theca cells is referred to as the “two-cell, two gonadotropin” 
theory (Ryan et al. 1968). It is also noteworthy that, in the 
ovary, androgens are not only precursors of estrogen pro-
duction, but also important drivers of the transition from 
primordial to antral follicle (Franks and Hardy 2018; Lebbe 
and Woodruff 2013). In addition, estrogens play a key role 
in regulating the hypothalamic–pituitary–gonadal axis by 
exerting both negative and positive feedback on pituitary 
FSH and LH release. Thus, chemical influences on steroi-
dogenesis will also affect folliculogenesis.
Follicular atresia is a process of follicular death that has 
features of both apoptosis and autophagy, and is believed 
to assure the ovulation of competent oocytes during repro-
ductive age. However, certain environmental cues, such as 
chemical exposure, can disturb this tightly regulated balance 
and lead to clinical pathologies such as POI, which is charac-
terized by, but not exclusively to, hormonal imbalances and 
a reduced ovarian reserve. In a recent review, the role for 
EDCs in inducing POI due to increased atresia in pre-antral 
follicles was highlighted (Vabre et al. 2017). One mechanism 
that may be involved in EDC-mediated follicle atresia is via 
AHR, as further explored below in pAOP 5 in Fig. 4.
pAOP‑5: “disrupted AHR signaling leads to follicle atresia 
and premature ovarian insufficiency”
This pAOP proposes to link AHR signaling to premature 
ovarian insufficiency and impaired reproduction in women. 
The development of this AOP relies on evidence collected 
from mouse models and incorporates human data from a 
xeno-transplantation model (Matikainen et al. 2001) and 
women cohort data (Eskenazi et al. 2010). In the ovary, AHR 
also controls the expression of proapoptotic proteins BAX 
(BCL2-associated X, apoptosis regulator) and HRK in the 
pre-antral follicles leading to direct induction of apoptosis. 
The resulting loss of follicles leads to a decrease of the ovar-
ian reserve and can result in premature ovarian insufficiency 
and early menopause.
Supporting evidence The number of primordial ovarian 
follicles (i.e., the size of the ovarian reserve) determines 
fertility in females. Activation of AHR can induce death of 
immature and early growing follicles in mice leading to a 
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reduction of the ovarian follicle pool (Jurisicova et al. 2007; 
Matikainen et  al. 2001; Pru et  al. 2009). This mechanism 
appears to be conserved between mouse and human (Juri-
sicova et al. 2007) and can lead to premature ovarian insuf-
ficiency and early menopause.
Evidence for  chemical triggers AHR-activating chemicals 
such as polycyclic aromatic hydrocarbons benzo[a]pyrene 
or dimethylbenz[a]anthracene, can induce primordial germ 
cell atresia and oocyte death via the intracellular apopto-
sis pathway in fetal and adult rodent ovaries, respectively 
(Matikainen et al. 2001, 2002; Neal et al. 2010). Polycyclic 
aromatic hydrocarbons found in tobacco smoke can activate 
AHR: offspring from mice exposed to polycyclic aromatic 
hydrocarbons (mimicking cigarette smoking) before preg-
nancy and during lactation displayed a significant reduction 
in primordial follicles (Jurisicova et al. 2007).
pAOP‑6: “early PI3K activation leads to premature ovarian 
insufficiency”
This pAOP proposes to link activation of PI3K signaling 
in primordial follicles to premature ovarian insufficiency, 
leading to impaired fertility in adult females. The develop-
ment of this AOP relies on evidence collected from mouse 
models and mechanistic information from both mouse and 
human models, showing that PI3K signaling controls early 
steps of follicle activation (Hsueh et al. 2015). This signaling 
pathway can be activated by various cell surface receptor 
tyrosine kinases, such as c-Kit, as well as by inhibition of 
PTEN (Phosphatase and TENsin homolog deleted on chro-
mosome 10). PI3K signaling stimulates early follicle growth. 
This leads to more follicles exiting the pool of dormant folli-
cles, which will reduce the ovarian reserve in the long term. 
Accelerated reduction of ovarian reserve can result in pre-
mature ovarian insufficiency and early menopause. Research 
has shown that this mechanism is conserved between mouse 
and human.
Supporting evidence Experimental support is derived from 
a limited number of studies; however, it is well established 
that the number of ovarian follicles at birth determines the 
reproductive lifespan (Wallace and Kelsey 2010). Increased 
activation of the follicle pool will, therefore, shorten the 
reproductive lifespan. Activation of PI3K has been shown 
to induce activation of primordial follicles in mice (Reddy 
et al. 2008). Also, estradiol increases phosphorylation and 
decreases activity of PTEN in vitro (Scully et al. 2014).
Evidence for  chemical triggers Exposure to di-ethylhexyl 
phthalate and its metabolite mono-ethylhexyl phthalate has 
been shown to accelerate growth of isolated mouse ovarian 
follicles in vitro, as well as in mice in vivo with concurrent 
activation of PI3K in follicles measured as pAkt (Hannon 
et al. 2014, 2015). In mice, this results in premature ovarian 
insufficiency (Hannon et al. 2016).
pAOP‑7: “decreased estradiol synthesis leads to alteration 
in ovarian cyclicity and impaired fertility in females”
This pAOP proposes to link inhibited steroidogenesis lead-
ing to lower estradiol levels and subsequently decreased 
ER action, which ultimately will result in modified ovar-
ian cyclicity. Strong evidence comes from animal stud-
ies, which is supported by human epidemiological data 
and in vitro studies using human cells. Cyclic maturation 
of follicles is strongly dependent on coordinated hypotha-
lamic–pituitary–gonadal axis function. Estradiol plays a key 
role in regulating the hypothalamic–pituitary–gonadal axis 
by exerting both negative and positive feedback on pitui-
tary FSH and LH release (Moenter et al. 2020). Key events 
include inhibited estradiol production by ovarian granulosa 
cells and altered ERα activation in neuronal cells leading to 
alterations in ovarian cyclicity.
Supporting evidence Correct ovarian cyclicity is essen-
tial for successful ovulation (Barbieri 2014). In addition, 
estrogen synthesized in the granulosa cells stimulates the 
maturation process of the primary follicle and endometrium 
for implantation. Disrupted ovarian cyclicity and modified 
follicle maturation can thus directly impact female fertility 
and is, therefore, considered an adverse health outcome. 
This is also observed in epidemiological studies. For exam-
ple, women with shorter menstrual cycles were less likely 
to conceive and women with longer or shorter cycles were 
more likely to have spontaneous abortion (Small et al. 2006).
Evidence for  chemical triggers In adult rats, bisphenol A 
exposure can cause a decreased number of antral follicles 
and corpora lutea, as well as disrupted estrous cycle asso-
ciated with delayed and lower amplitude LH surge (López-
Rodríguez et  al. 2019). Numerous studies link bisphenol A 
exposure to aromatase inhibition in granulosa cells and delay 
or suppression of LH surge resulting in modified ovarian 
cyclicity (Viguié et  al. 2018). Di-(2-ethylhexyl) adipate can 
shorten the average length of the estrus cycle in rats (Wato 
et al. 2009), whereas acetyl tributyl citrate has been shown to 
do so in mice (Rasmussen et al. 2017). In humans, exposure to 
organophosphate pesticides has been related to a higher risk of 
irregular menstrual cycles and shorter menstrual bleed dura-
tion among Chinese women (Zhang et al. 2019). Consump-
tion of phytoestrogen-rich soy foods increases menstrual cycle 
length in healthy premenopausal women (Hooper et al. 2009; 
Kumar et al. 2002). A reduction in LH concentrations was also 
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found in healthy premenopausal women after a single dose of 
the phytoestrogen 8-prenylnaringenin (Rad et al. 2006).
pAOP‑8: “decreased INSL3 synthesis leads to reduced 
follicle maturation and impaired fertility in females”
This pAOP proposes to link disrupted INSL3 (Insulin-like 
factor 3) signaling with follicle maturation. Evidence derives 
from both animal and human studies. In the adult ovary, 
INSL3 is mainly produced by the theca cells across species 
and acts by paracrine signaling on the oocytes. In rodents, loss 
of INSL3 compromises female fertility. In cow ovaries, INSL3 
stimulates antral follicle growth in concert with LH and sex 
steroids. In humans, circulating INSL3 levels are elevated in 
women with PCOS.
Supporting evidence INSL3 is expressed in ovarian theca 
cells (Bathgate et al. 1996; Ivell and Anand-Ivell 2018) and 
female Insl3 knockout mice display reduced fertility (Nef 
and Parada 1999) or increased rate of follicular atresia and 
apoptosis (Spanel-Borowski et al. 2001). Studies suggest that 
somatic INSL3 act on germ cells via the G protein-coupled 
receptor RXFP2 (LGR8) and, by so doing, initiate oocyte 
maturation (Kawamura et al. 2004) by stimulating GDF9 pro-
duction (Xue et  al. 2014). In turn, this stimulates androgen 
synthesis in the theca cells (Xue et al. 2014). In cultured theca 
cells from cow ovaries, RNAi-mediated knockdown of INSL3 
elicited a reduction in CYP17A1 (Cytochrome P450 family 
17, subfamily A, member 1) mRNA and reduction in andros-
tenedione production (Glister et al. 2013). In humans, circulat-
ing INSL3 levels may be a measure of theca cell function in 
women of reproductive age (Ivell and Anand-Ivell 2018), with 
elevated levels observed in women with PCOS (Anand-Ivell 
et al. 2013).
Evidence for  chemical triggers In adult rats, prenatal expo-
sure before mating and during pregnancy to a mixture of bro-
minated flame retardants downregulated Insl3 and Cyp17a1 
expression in the ovary, but increased circulating androgen 
levels and caused increased number of (pre)antral follicles 
and antral follicle size in the dams (Lefèvre et al. 2016). There 
are numerous studies reporting disrupted INSL3 expression 
in testes following exposure to industrial chemicals such 
as phthalates leading to male reproductive tract anomalies 
(Anand-Ivell et al. 2018; Wang et al. 2019). It can be spec-
ulated that effects in the ovaries would be similar to effects 
seen in testes; however, direct evidence in the human female 
is lacking.
AOP‑9: “disrupted AR activity leads to altered follicle 
growth and impaired fertility”
This pAOP proposes to link impaired activation of the 
AR (Androgen receptor) to adverse effects on reproduc-
tive capacity. The development of this AOP relies on evi-
dence collected from rodent and pig models. The key events 
include impaired AR activation through AR antagonism fol-
lowed by impaired follicle growth and ovulation.
Supporting evidence AR is expressed in granulosa cells 
and is involved in the regulation of follicle activation and 
growth, since androgens can increase granulosa cell respon-
siveness to FSH (Franks and Hardy 2018; Lebbe and 
Woodruff 2013). Testosterone exposure in mice induces 
primordial follicle activation through both PI3K pathway-
activation (Yang et al. 2010) and insulin-like growth factor 
1 (IGF-1) signaling (Vendola et al. 1998, 1999). Androgen 
exposure induces growth of pre-antral and antral follicles, 
and mice lacking AR display impaired follicle maturation 
(Franks and Hardy 2018; Lebbe and Woodruff 2013). A 
study using cultured mouse follicles suggests that androgen 
homeostasis in the developing pre-antral and antral follicle 
is necessary to ensure optimal growth, steroidogenesis, and 
oocyte maturation (Lebbe et al. 2017).
Evidence for chemical triggers Many EDCs are considered 
anti-androgenic based on their ability to block AR action in 
developing male rodents (Gray et al. 2006; Kortenkamp and 
Faust 2010; Schwartz et  al. 2019; Vinggaard et  al. 2008). 
Neonatal exposure to the AR antagonist flutamide delays 
initiation of folliculogenesis and reduces ovarian cell prolif-
eration in pigs. In vitro, treatment of mouse pre-antral fol-
licles with the AR antagonist enzalutamide (MDV) reduces 
follicle growth and counteracts the DHT-stimulated transi-
tion to antral follicles (Lebbe et al. 2017).
pAOP‑10: “DNA methylation in LHCGR promoter leads 
to disturbed ovulation and impaired fertility in females”
This pAOP proposes to link DNA methylation in the tran-
scription start site of the LHCGR (Luteinizing hormone/cho-
riogonadotropin receptor) gene to impaired female fertility. 
LHCGR, also known as LH receptor, is necessary for trig-
gering processes leading to ovulation and meiotic maturation 
of oocytes. The development of this AOP relies on evidence 
collected from zebrafish and mouse, and LHCGR appears to 
have evolutionary preserved roles.
Supporting evidence Loss of signaling through the LHCGR 
cascades can cause atresia of mature oocytes in zebrafish 
(Migliaccio et al. 2018; Santangeli et al. 2016) and anovula-
tion in mouse and human (Arroyo et al. 2020). For instance, 
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increased DNA demethylation of LHCGR is observed in 
DHEA-induced PCOS mouse model (Zhu et al. 2010) and 
human granulosa cells of women with PCOS (Sagvekar 
et al. 2019).
Evidence for  chemical triggers Bisphenol A can disturb 
ovarian H3K4me3 and H3K27me3 patterns in the transcrip-
tional start site of the LHCGR gene promoter, leading to 
downregulation of its transcript, as well as the expression 
of its downstream target PGRMC1 (Progesterone recep-
tor membrane component 1). Increased level of atresia and 
complete block of ovulation was observed in adult zebrafish 
after 3 weeks of exposure to bisphenol A (Santangeli et al. 
2016). PGRMC1, in turn, is involved in oocyte meiosis as 
its gene disruption in zebrafish leads to reduced response 
to progestin and decreased number of oocytes undergoing 
meiotic maturation (Wu et al. 2018).
Test methods
A big challenge with developing AOPs for female reproduc-
tive disorders is the many knowledge gaps with respect to 
disease etiologies, not least at the mechanistic level. The 
AOP concept builds on the idea that we can improve both 
speed and accuracy of chemical testing by relying more on 
alternative test methods than on experimental animal test-
ing. This requires, and will stimulate, the development of 
new alternative test methods, being it in silico, in chemico 
or in vitro, as well as improvement of endpoints in exist-
ing in vivo OECD-approved test guidelines for regulatory 
testing.
In vivo toxicity test guidelines include examination of 
ovarian weights and histology, estrous cyclicity and exami-
nation of pregnancy rate, fertility and pup survival, which 
can be considered quite crude and non-sensitive endpoints. 
The OECD guidance document 150 describes a Concep-
tual Framework for Testing and Assessment of Endocrine 
Disrupters that helps organize available test methods at dif-
ferent levels (L1-5) of biological organization to determine 
additional testing needs or conclude about the potential 
endocrine disrupter action of a chemical (OECD 2018a). 
Lower levels include non-test and in vitro assays, and higher 
levels include in vivo information with increasing degree 
of complexity. This document provides guidance for how 
to interpret data obtained from OECD Test Guidelines and 
other standardized test methods that can be used to evalu-
ate chemicals for endocrine disruption primarily on those 
operating via estrogen, androgen, thyroid, steroidogenesis 
(EATS) modalities. In this review, we have included pAOPs 
that do not necessarily follow a classical endocrine mode 
of action. This would include those for disrupted meiosis 
(Fig. 2) and ectopic PI3K activation (Fig. 4). Nevertheless, 
they are equally important with regard to test strategies to 
prevent adverse reproductive outcomes, as the end result 
is the same: compromised female reproductive health and 
function. Also, our ten proposed pAOPs all comprise a set 
of KEs that do not necessarily correspond with a current 
OECD Test Guideline. In fact, a main goal of the FREIA 
project is to use AOPs to explain the mechanisms underly-
ing chemically-induced female reproductive disorders and 
to highlight areas, where we should focus on improving or 
developing new test assays (https ://www.freia proje ct.eu). 
Below, we briefly present the current assay status for some 
of the most recurrent KEs in the pAOPs presented in this 
review.
Key events related to meiosis
Testing for disrupted meiosis, or germ cell toxicity in gen-
eral, is a challenge. This is particularly true for female germ 
cells, as they are much more cumbersome to harvest than 
their male counterpart, sperm. There are some interesting 
models being developed in non-mammalian systems, includ-
ing yeast, fruit fly and flatworm (Ferreira and Allard 2015) 
that could potentially be adapted to study disrupted meio-
sis, depending on what modalities are being looked at. This 
could reduce reliance on in vivo KE, for instance measuring 
fertility rates in rodents. Since retinoic acid is a key initia-
tor of germ cell meiosis, quantitative assays measuring reti-
noic acid levels in in vitro and in vivo samples are obvious 
choices; and several assays are already available (Grignard 
et al. 2020). As for CYP26B1, or CYP26A1, simply measur-
ing ectopic gene or protein expression in fetal ovaries would 
suffice.
Regarding disrupted assembly of synaptonemal complex 
(pAOP 3), we are not aware of any current in vitro assays, or 
assays that could be adopted or modified to become fit-for-
purpose. Effects on the synaptonemal complex and recom-
bination are highly germ cell-specific and require cells to 
be analyzed while in meiosis I. SYCP3 and MLH1 (MutL 
homolog 1) immunolabelling can be performed to assess 
synapsis and recombination levels in in vivo studies, as done 
by others (Hunt et al. 2012; Susiarjo et al. 2007). While this 
is technically feasible, it is probably too laborious and might 
not be attainable to include in guideline protocols. However, 
analysing the aneuploidy rate in ovulated oocytes could pro-
vide the indirect measure to estimate the effect of EDCs on 
the fidelity of the meiotic segregation of chromosomes.
Key events related to receptor interactions
Several of the pAOPs include KEs related to receptor 
interaction, for which there are already several assays 
and test methods available. For AR inhibition, the stably 
transfected AR-EcoScreen™ cell line can be used to test 
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both agonism and antagonism of human AR by follow-
ing OECD test guideline 458 (OECD 2016b). Similarly, 
there is an OECD performance based test guideline assay 
to study (ant)agonism at the ERα (OECD 2016a). We are 
currently developing an ERβ assay in the FREIA project 
using a high-content imaging platform. An additional 
assay of potential interest in relation to estrogenic activ-
ity is a fluorescent vtg1 (vitellogenin 1) enhancer knock-in 
Zebrafish model recently developed (Abdelmoneim et al. 
2020). For AHR (ant)agonism, several assays exists (Laier 
et al. 2003); however, at the time of writing they are not 
included in any OECD test guideline.
Key events related to steroidogenesis
For measuring changes in steroid sex hormone synthe-
sis, the already validated in vitro OECD test guideline 
H295R steroidogenesis assay (OECD TG 456) is an obvi-
ous choice (OECD 2011). It is in level 2 of the concep-
tual framework providing data about selected endocrine 
mechanisms and pathways (OECD 2018a). This cell line 
is derived from an adrenocortico carcinoma from a female 
patient and produces all of the steroid hormones in the 
classical steroidogenic pathway. The H295R steroidogenic 
assay enables the measurement of steroid sex hormone lev-
els from the culture medium, as well as cellular expression 
level of steroidogenic enzymes. The gonads, however, dis-
play different pathways for steroidogenesis, including an 
alternative or “backdoor” pathway (Marti et al. 2017). This 
means that assays using theca or granulosa cells might be 
more relevant to detect disrupted ovarian steroidogenesis. 
We are currently investigating whether the current H295R 
steroidogenic assay is sufficient to capture potential effects 
of EDCs on the more complex, ovarian two-cell collabora-
tion in steroidogenesis that is essential for ovarian estra-
diol production. It is conceivable that systems using intact 
ovaries or multiple cell types may reveal effects not detect-
able using an adrenal assay.
When addressing steroidogenesis, it might be useful to 
study interactions with specific steroidogenic enzymes, such 
as CYP17a1 or CYP19 (aromatase). The conceptual frame-
work level 2 also includes an assay to study interactions 
with aromatase activity, i.e., aromatase assay (United States 
Environmental Protection Agency (US EPA) TG OPPTS 
890.1200). While this test guideline has only been validated 
in the US, and not been accepted by the OECD, it is a com-
monly used assay in ED assessment in US. For interactions 
with CYP17A1, there are no current test guideline available. 
Previous studies have shown that this could be an added 
value to the conceptual framework, as CYP17 can be a target 
for EDCs and that this interaction differs from interactions 
with CYP19/aromatase (Roelofs et al. 2013).
Key events related to folliculogenesis
Chemical disruption of folliculogenesis in vivo can be ana-
lyzed by quantification of the resting oocyte pool, growing 
ovarian follicles, as well as atretic follicles using histologi-
cal sections. Such quantifications have been performed in 
several in vivo studies (Johansson et al. 2016; Mazaud et al. 
2002; Patel et al. 2017), but it is a time-consuming process 
and would benefit from automation protocols. This is cur-
rently being explored in the FREIA project.
Specific assays need to be developed for KEs leading 
up to AOs that are measureable at the morphological level. 
Ex vivo models using exposed ovaries, or pieces of ova-
ries, at different stages of development can be useful for 
determining effect on each step of folliculogenesis, but no 
standard protocols are currently in focus for test method 
development (Hao et al. 2018). In culture systems using 
intact ovaries or multiple cell types, interactions with LHCR 
expression or INSL3 levels could be implemented. INSL3 
levels can be measured in serum samples. It is worth investi-
gating whether circulating INSL3 levels can be used as pre-
dictive biomarkers for female reproductive toxicity. Finally, 
activation of the PI3K-Akt signaling pathway is currently 
investigated by time-consuming quantification of the num-
ber of follicles positive for phosphorylated-Akt (pAkt) by 
immunostaining or by FOXO3 cytoplasmic translocation on 
histological slides from in vivo or ex vivo studies. However, 
cell-based assays specifically targeting this pathway could 
be beneficial in the long term.
Perspectives
Although the AOP framework was proposed more than a 
decade ago, there are still not many ‘encyclopedic AOPs’ 
in the AOP-wiki. Notably, there is only one AOP (AOP7) 
that addresses female reproductive disorders in mammals 
(AOPwiki.org). Clearly, there is an urgent need to substan-
tially update the AOP database and include more AOPs 
focusing on female reproductive toxicity. In this review, we 
have proposed ten pAOPs that we believe will be of use to 
researchers and regulators alike going forward. Neither of 
the pAOPs are yet included in the AOPwiki and much work 
remains before they become encyclopedic. From our synthe-
sis of available literature, however, it is clear that alternative 
test assays are available to assess effects of chemicals on 
some early KEs. However, to use these alternative assays 
to predict AOs, plausible cause–effect relationships must 
be established to underpin any reliable data interpretation. 
Clearly, this requires an intensified effort towards describing 
female reproductive disease etiologies in the years to come 
if we are to reach our chemical safety assessment goals. 
The possibility of including more female KEs and AOs and 
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thereby enhancing some of the in vivo Test Guidelines could 
be a way forward in the shorter term. So too, the discovery 
of robust biomarkers for female reproductive disorders, for 
instance the recently suggested CALB2 (Johansson et al. 
2020), could prove very valuable additions to testing strate-
gies as well as for clinical purposes.
Although the ten proposed pAOPs need additional work 
to be included in the AOPwiki, some of them rest on fairly 
solid ground. In particular, we envision pAOPs 1, 2, and 5 
to gain rapid traction and, hopefully, populate the AOPwiki 
in the near future. This also extends to assay development or 
implementation of pre-existing assays by linking to shared 
KEs from other AOPs from separate biological systems. In 
fact, the premise of the current review is for more AOPs 
related to female reproductive disorders to be developed and 
included in the AOP-KB to serve as guides for risk assessors 
and chemical regulators under different jurisdictions.
Funding This work was funded by the EU Horizon 2020 project 
FREIA (Grant Number 825100).
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest pertaining to this work.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
Abdelmoneim A, Clark CL, Mukai M (2020) Fluorescent reporter 
zebrafish line for estrogenic compound screening generated 
using a CRISPR/Cas9-mediated knock-in system. Toxicol Sci 
173:336–346. https ://doi.org/10.1093/toxsc i/kfz22 4
Abel MH, Wootton AN, Wilkins V, Huhtaniemi I, Knight PG, Charlton 
HM (2000) The effect of a null mutation in the follicle-stimulat-
ing hormone receptor gene on mouse reproduction. Endocrinol-
ogy 141:1795–1803. https ://doi.org/10.1210/endo.141.5.7456
Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello 
AR, Dolce V, Abonante S, Pezzi V, Maggiolini M (2015) Effects 
of atrazine on estrogen receptor α- and G protein-coupled recep-
tor 30-mediated signaling and proliferation in cancer cells and 
cancer-associated fibroblasts. Environ Health Perspect 123:493–
499. https ://doi.org/10.1289/ehp.14085 86
Anand-Ivell R, Cohen A, Nørgaard-Pedersen B, Jönsson BAG, Bonde 
JP, Hougaard DM, Lindh CH, Toft G, Lindhard MS, Ivell R 
(2018) Amniotic fluid INSL3 measured during the critical time 
window in human pregnancy relates to cryptorchidism, hypospa-
dias, and phthalate load: a large case-control study. Front Physiol 
9:406. https ://doi.org/10.3389/fphys .2018.00406 
Anand-Ivell R, Tremellen K, Dai Y, Heng K, Yoshida M, Knight PG, 
Hale GE, Ivell R (2013) Circulating insulin-like factor 3 (INSL3) 
in healthy and infertile women. Hum Reprod 28:3093–3102. 
https ://doi.org/10.1093/humre p/det34 9
Anderson RA, McIlwain L, Coutts S, Kinnell HL, Fowler PA, Childs 
AJ (2015) Activation of the aryl hydrocarbon receptor by a 
component of cigarette smoke reduces germ cell proliferation 
in the human fetal ovary. Mol Hum Reprod 21:753. https ://doi.
org/10.1093/moleh r/gav04 4
Ankley GT, Edwards SW (2018) The adverse outcome pathway: a mul-
tifaceted framework supporting 21st century toxicology. Curr 
Opin Toxicol 9:1–7. https ://doi.org/10.1016/j.cotox .2018.03.004
Arroyo A, Kim B, Yeh J (2020) Luteinizing hormone action in human 
oocyte maturation and quality: signaling pathways, regulation, 
and clinical impact. Reprod Sci 27:1223–1252. https ://doi.
org/10.1007/s4303 2-019-00137 -x
Axmon A, Rylander L, Strömberg U, Hagmar L (2000) Time to preg-
nancy and infertility among women with a high intake of fish 
contaminated with persistent organochlorine compounds. Scand J 
Work Environ Health 26:199–206. https ://doi.org/10.5271/sjweh 
.532
Barbieri RL (2014) The endocrinology of the menstrual 
cycle. Methods Mol Biol 1154:145–169. https ://doi.
org/10.1007/978-1-4939-0659-8_7
Bathgate R, Balvers M, Hunt N, Ivell R (1996) Relaxin-like factor 
gene is highly expressed in the bovine ovary of the cycle and 
pregnancy: sequence and messenger ribonucleic acid analysis. 
Biol Reprod 55:1452–1457. https ://doi.org/10.1095/biolr eprod 
55.6.1452
Bolcun-Filas E, Schimenti JC (2012) Genetics of meiosis and recombi-
nation in mice. Int Rev Cell Mol Biol 298:179–227. https ://doi.
org/10.1016/B978-0-12-39430 9-5.00005 -5
Bowles J, Feng CW, Ineson J, Miles K, Spiller CM, Harley VR, Sinclair 
AH, Koopman P (2018) Retinoic acid antagonizes testis develop-
ment in mice. Cell Rep 24:1330–1341. https ://doi.org/10.1016/j.
celre p.2018.06.111
Bowles J, Knight D, Smith C, Wilhelm D, Richman J, Mamiya S, 
Yashiro K, Chawengsaksophak K, Wilson MJ, Rossant J, Ham-
ada H, Koopman P (2006) Retinoid signaling determines germ 
cell fate in mice. Science 312:596–600. https ://doi.org/10.1126/
scien ce.11256 91
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO (2016) 
The prevalence and phenotypic features of polycystic ovary 
syndrome: a systematic review and meta-analysis. Hum Reprod 
31:2841–2855. https ://doi.org/10.1093/humre p/dew21 8
Brieño-Enríquez MA, Robles P, Camats-Tarruella N, García-Cruz R, 
Roig I, Cabero L, Martínez F, Caldés MG (2011) Human mei-
otic progression and recombination are affected by Bisphenol 
A exposure during in vitro human oocyte development. Hum 
Reprod 26:2807–2818. https ://doi.org/10.1093/humre p/der24 9
Broekmans FJ, Visser JA, Laven JS, Broer SL, Themmen AP, Fauser 
BC (2008) Anti-Müllerian hormone and ovarian dysfunction. 
Trends Endocrinol Metab 19:340–347. https ://doi.org/10.1016/j.
tem.2008.08.002
Buck Louis GM, Cooney MA, Peterson CM (2011) The ovarian dys-
genesis syndrome. J Dev Orig Health Dis 2:25–35. https ://doi.
org/10.1017/S2040 17441 00006 93
Buck Louis GM, Sundaram R, Schisterman EF, Sweeney AM, Lynch 
CD, Gore-Langton RE, Chen Z, Kim S, Caldwell KL, Barr DB 
(2012) Heavy metals and couple fecundity, the LIFE study. 
3374 Archives of Toxicology (2020) 94:3359–3379
1 3
Chemosphere 87:1201–1207. https ://doi.org/10.1016/j.chemo 
spher e.2012.01.017
Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta 
O (2006) Anti-Müllerian hormone inhibits initiation of growth 
of human primordial ovarian follicles in vitro. Hum Reprod 
21:2223–2227. https ://doi.org/10.1093/humre p/del16 5
Childs AJ, Cowan G, Kinnell HL, Anderson RA, Saunders PT (2011) 
Retinoic acid signalling and the control of meiotic entry in 
the human fetal gonad. PLoS ONE 6:e20249. https ://doi.
org/10.1371/journ al.pone.00202 49
Chourasia TK, Pang Y, Thomas P (2015) The catecholestrogen, 
2-hydroxyestradiol-17beta, acts as a G protein-coupled estrogen 
receptor 1 (GPER/GPR30) antagonist to promote the resumption 
of meiosis in zebrafish oocytes. Biol Reprod 92:69. https ://doi.
org/10.1095/biolr eprod .114.12567 4
Crain DA, Janssen SJ, Edwards TM, Heindel J, Ho SM, Hunt P, Iguchi 
T, Juul A, McLachlan JA, Schwartz J, Skakkebaek N, Soto AM, 
Swan AM, Walker C, Woodruff TK, Woodruff TJ, Giudice LC, 
Guillette LJJ (2008) Female reproductive disorders: the roles 
of endocrine-disrupting compounds and developmental timing. 
Fertil Steril 90:911–940. https ://doi.org/10.1016/j.fertn stert 
.2008.08.067
Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM 
(1996) Growth differentiation factor-9 is required during early 
ovarian folliculogenesis. Nature 383:531–535. https ://doi.
org/10.1038/38353 1a0
Dong S, Terasaka S, Kiyama R (2011) Bisphenol A induces a rapid 
activation of Erk1/2 through GPR30 in human breast cancer 
cells. Environ Pollut 159:212–218. https ://doi.org/10.1016/j.
envpo l.2010.09.004
Draskau MK, Spiller C, Boberg J, Bowles J, Svingen T (2020) Devel-
opmental biology meets toxicology: contributing reproductive 
mechanisms to build adverse outcome pathways. Mol Hum 
Reprod 26:111–116. https ://doi.org/10.1093/moleh r/gaaa0 01
Durlinger AL, Visser JA, Themmen AP (2002) Regulation of ovar-
ian function: the role of anti-Müllerian hormone. Reproduction 
124:601–609. https ://doi.org/10.1530/rep.0.12406 01
Ehrlich S, Williams PL, Missmer SA, Flaws JA, Ye X, Calafat AM, 
Petrozza JC, Wright D, Hauser R (2012) Urinary bisphenol A 
concentrations and early reproductive health outcomes among 
women undergoing IVF. Hum Reprod 27:3583–3592. https ://
doi.org/10.1093/humre p/des32 8
Eisenberg VH, Weil C, Chodick G, Shalev V (2018) Epidemiology of 
endometriosis: a large population-based database study from a 
healthcare provider with 2 million members. BJOG 125:55–62. 
https ://doi.org/10.1111/1471-0528.14711 
Eskenazi B, Warner M, Marks AR, Samuels S, Needham L, Brambilla 
P, Mocarelli P (2010) Serum dioxin concentrations and time to 
pregnancy. Epidemiology 21:224–231. https ://doi.org/10.1097/
EDE.0b013 e3181 cb8b9 5
Ferreira DW, Allard P (2015) Models of germ cell development and 
their application for toxicity studies. Environ Mol Mutagen 
56:637–649. https ://doi.org/10.1002/em.21946 
Filippou P, Homburg R (2017) Is foetal hyperexposure to androgens a 
cause of PCOS? Hum Reprod Update 23:421–432. https ://doi.
org/10.1093/humup d/dmx01 3
Fowler PA, Bellingham M, Sinclair KD, Evans NP, Pocar P, Fischer 
B, Schaedlich K, Schmidt JS, Amezaga MR, Bhattacharya S, 
Rhind SM, O’Shaughnessy PJ (2012) Impact of endocrine-
disrupting compounds (EDCs) on female reproductive health. 
Mol Cell Endocrinol 355:231–239. https ://doi.org/10.1016/j.
mce.2011.10.021
Fowler PA, Childs AJ, Courant F, MacKenzie A, Rhind SM, Antignac 
JP, Le Bizec B, Filis P, Evans F, Flannigan S, Maheshwari A, 
Bhattacharya S, Monteiro A, Anderson RA, O’Shaughnessy PJ 
(2014) In utero exposure to cigarette smoke dysregulates human 
fetal ovarian developmental signalling. Hum Reprod 29:1471–
1489. https ://doi.org/10.1093/humre p/deu11 7
Fraison E, Crawford G, Casper G, Harris V, Ledger W (2019) Preg-
nancy following diagnosis of premature ovarian insufficiency: a 
systematic review. Reprod Biomed Online S1472–6483:30396–
30397. https ://doi.org/10.1016/j.rbmo.2019.04.019
Franks S, Hardy K (2018) Androgen action in the ovary. Front 
Endocrinol (Lausanne) 9:452. https ://doi.org/10.3389/fendo 
.2018.00452 
Frydman N, Poulain M, Arkoun B, Duquenne C, Tourpin S, Messi-
aen S, Habert R, Rouiller-Fabre V, Benachi A, Livera G (2017) 
Human foetal ovary shares meiotic preventing factors with 
the developing testis. Hum Reprod 32:631–642. https ://doi.
org/10.1093/humre p/dew34 3
Gely-Pernot A, Saci S, Kernanec PY, Hao C, Giton F, Kervarrec C, 
Tevosian S, Mazaud-Guittot S, Smagulova F (2017) Embryonic 
exposure to the widely-used herbicide atrazine disrupts meiosis 
and normal follicle formation in female mice. Sci Rep 7:3526. 
https ://doi.org/10.1038/s4159 8-017-03738 -1
Ghiasi M, Kulkarni MT, Missmer SA (2020) Is endometriosis more 
common and more severe than it was 30 years ago? J Minim 
Invasive Gynecol 27:452–461. https ://doi.org/10.1016/j.
jmig.2019.11.018
Glister C, Satchell L, Bathgate RA, Wade JD, Dai Y, Ivell R, Anand-
Ivell R, Rodgers RJ, Knight PG (2013) Functional link between 
bone morphogenetic proteins and insulin-like peptide 3 signaling 
in modulating ovarian androgen production. Proc Natl Acad Sci 
USA 110:E1426–1435. https ://doi.org/10.1073/pnas.12222 16110 
Goldrat O, Delbaere A (2018) PCOS: update and diagnostic approach. 
Clin Biochem 62:24–31. https ://doi.org/10.1016/j.clinb ioche 
m.2018.09.001
Golezar S, Ramezani-Tehrani F, Khazaei S, Ebadi A, Keshavarz Z 
(2019) The global prevalence of primary ovarian insufficiency 
and early menopause: a meta-analysis. Climacteric 22:403–411. 
https ://doi.org/10.1080/13697 137.2019.15747 38
Gougeon A (1986) Dynamics of follicular growth in the human: a 
model from preliminary results. Hum Reprod 1:81–87. https ://
doi.org/10.1093/oxfor djour nals.humre p.a1363 65
Gray LEJ, Wilson VS, Stoker T, Lambright C, Furr J, Noriega N, 
Howdeshell K, Ankley GT, Guillette L (2006) Adverse effects 
of environmental antiandrogens and androgens on reproductive 
development in mammals. Int J Androl 29:96–104. https ://doi.
org/10.1111/j.1365-2605.2005.00636 .x
Grignard E, Håkansson H, Munn S (2020) Regulatory needs and activi-
ties to address the retinoid system in the context of endocrine 
disruption: the European viewpoint. Reprod Toxicol 93:250–258. 
https ://doi.org/10.1016/j.repro tox.2020.03.002
Grindler NM, Allsworth JE, Macones GA, Kannan K, Roehl KA, 
Cooper AR (2015) Persistent organic pollutants and early men-
opause in U.S. women. PLoS ONE 10:e0116057. https ://doi.
org/10.1371/journ al.pone.01160 57
Grive KJ, Freiman RN (2015) The developmental origins of the mam-
malian ovarian reserve. Development 142:2554–2563. https ://
doi.org/10.1242/dev.12521 1
Habbema JD, Collins J, Leridon H, Evers JL, Lunenfeld B, te Velde 
ER (2004) Towards less confusing terminology in reproductive 
medicine: a proposal. Hum Reprod 19:1497–1501. https ://doi.
org/10.1093/humre p/deh30 3
Hannon PR, Brannick KE, Wang W, Flaws JA (2015) Mono(2-ethyl-
hexyl) phthalate accelerates early folliculogenesis and inhibits 
steroidogenesis in cultured mouse whole ovaries and antral fol-
licles. Biol Reprod 92:120. https ://doi.org/10.1095/biolr eprod 
.115.12914 8
3375Archives of Toxicology (2020) 94:3359–3379 
1 3
Hannon PR, Niermann S, Flaws JA (2016) Acute exposure to di(2-
ethylhexyl) phthalate in adulthood causes adverse reproduc-
tive outcomes later in life and accelerates reproductive aging in 
female mice. Toxicol Sci 150:97–108. https ://doi.org/10.1093/
toxsc i/kfv31 7
Hannon PR, Peretz J, Flaws JA (2014) Daily exposure to di(2-ethyl-
hexyl) phthalate alters estrous cyclicity and accelerates primor-
dial follicle recruitment potentially via dysregulation of the phos-
phatidylinositol 3-kinase signaling pathway in adult mice. Biol 
Reprod 90:136. https ://doi.org/10.1095/biolr eprod .114.11903 2
Hao J, Tuck AR, Sjödin MOD, Lindberg J, Sand A, Niklasson B, 
Argyraki M, Hovatta O, Damdimopoulou P (2018) Resvera-
trol supports and alpha-naphthoflavone disrupts growth of 
human ovarian follicles in an in vitro tissue culture model. 
Toxicol Appl Pharmacol 338:73–82. https ://doi.org/10.1016/j.
taap.2017.11.009
Hassold T, Hall H, Hunt P (2007) The origin of human aneuploidy: 
where we have been, where we are going. Hum Mol Genet 
16(Spec No 2):R203–208. https ://doi.org/10.1093/hmg/ddm24 3
Hassold T, Hunt P (2001) To err (meiotically) is human: the genesis 
of human aneuploidy. Nat Rev Genet 2:280–291. https ://doi.
org/10.1038/35066 065
Hatch EE, Troisi R, Wise LA, Hver M, Palmer JR, Titus-Ernstoff L, 
Strohsnitter W, Kaufman R, Adam E, Noller KL, Herbst AL, 
Robbov S, Hartge P, Hoover RN (2006) Age at natural meno-
pause in women exposed to diethylstilbestrol in utero. Am J Epi-
demiol 164:682–688. https ://doi.org/10.1093/aje/kwj25 7
Hooper L, Ryder JJ, Kurzer MS, Lampe JW, Messina MJ, Phipps WR, 
Cassidy A (2009) Effects of soy protein and isoflavones on cir-
culating hormone concentrations in pre- and post-menopausal 
women: a systematic review and meta-analysis. Hum Reprod 
Update 15:423–440. https ://doi.org/10.1093/humup d/dmp01 0
Hsueh AJ, Kawamura K, Cheng Y, Fauser BC (2015) Intraovarian 
control of early folliculogenesis. Endocr Rev 36:1–24. https ://
doi.org/10.1210/er.2014-1020
Hu Y, Wen S, Yuan D, Peng L, Zeng R, Yang Z, Liu Q, Xu L, Kang 
D (2018) The association between the environmental endocrine 
disruptor bisphenol A and polycystic ovary syndrome: a system-
atic review and meta-analysis. Gynecol Endocrinol 34:370–377. 
https ://doi.org/10.1080/09513 590.2017.14059 31
Hunt PA, Hassold TJ (2008) Human female meiosis: what makes 
a good egg go bad? Trends Genet 24:86–93. https ://doi.
org/10.1016/j.tig.2007.11.010
Hunt PA, Koehler KE, Susiarjo M, Hodges CA, Ilagan A, Voigt RC, 
Thomas S, Thomas BF, Hassold TJ (2003) Bisphenol a expo-
sure causes meiotic aneuploidy in the female mouse. Curr Biol 
13:546–553. https ://doi.org/10.1016/s0960 -9822(03)00189 -1
Hunt PA, Lawson C, Gieske M, Murdoch B, Smith C, Marre A, Has-
sold T, VandeVoort CA (2012) Bisphenol A alters early oogen-
esis and follicle formation in the fetal ovary of the rhesus mon-
key. Proc Natl Acad Sci USA 109:17525–17530. https ://doi.
org/10.1073/pnas.12078 54109 
Hunt PA, Sathyanarayana S, Fowler PA, Trasande L (2016) Female 
reproductive disorders, diseases, and costs of exposure to 
endocrine disrupting chemicals in the European Union. J Clin 
Endocrinol Metab 101:1562–1570. https ://doi.org/10.1210/
jc.2015-2873
Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner 
E, Dabadghao P, Darendeliler F, Elbarbary NS, Gambineri A, 
Garcia Rudaz C, Hoeger KM, López-Bermejo A, Ong K, Peña 
AS, Reinehr T, Santoro N, Tena-Sempere M, Tao R, Yildiz BO, 
Alkhayyat H, Deeb A, Joel D, Horikawa R, de Zegher F, Lee 
PA (2017) An international consortium update: pathophysiol-
ogy, diagnosis, and treatment of polycystic ovarian syndrome 
in adolescence. Horm Res Paediatr 88:371–395. https ://doi.
org/10.1159/00047 9371
Ivell R, Anand-Ivell R (2018) Insulin-like peptide 3 (INSL3) is a 
major regulator of female reproductive physiology. Hum Reprod 
Update 24:639–651. https ://doi.org/10.1093/humup d/dmy02 9
Jenkins J, Daya S, Kremer J, Balasch J, Barratt C, Cooke I, Lawford-
Davies J, De Sutter P, Suikari AM, Neulen J, Nygren K (2004) 
European classification of infertility taskforce (ECIT) response to 
Habbema et al., ’towards less confusing terminology in reproduc-
tive medicine: a proposal’. Hum Reprod 19:2687–2688. https ://
doi.org/10.1093/humre p/deh49 9
Jensen TK, Joffe M, Scheike T, Skytthe A, Gaist D, Petersen I, Chris-
tensen K (2006) Early exposure to smoking and future fecundity 
among Danish twins. Int J Androl 29:603–613. https ://doi.org/1
0.1111/j.1365-2605.2006.00701 .x
Johansson HK, Jacobsen PR, Hass U, Svingen T, Vinggaard AM, 
Isling LK, Axelstad M, Christiansen S, Boberg J (2016) Peri-
natal exposure to mixtures of endocrine disrupting chemicals 
reduces female rat follicle reserves and accelerates reproductive 
aging. Reprod Toxicol 61:186–194. https ://doi.org/10.1016/j.
repro tox.2016.03.045
Johansson HKL, Svingen T, Boberg J, Fowler PA, Stead D, Vinggaard 
AM, Filis P (2020) Calretinin is a novel candidate marker for 
adverse ovarian effects of early life exposure to mixtures of endo-
crine disruptors in the rat. Arch Toxicol 94:1241–1250. https ://
doi.org/10.1007/s0020 4-020-02697 -3
Johansson HKL, Svingen T, Fowler PA, Vinggaard AM, Boberg J 
(2017) Environmental influences on ovarian dysgenesis—devel-
opmental windows sensitive to chemical exposures. Nat Rev 
Endocrinol 13:400–414. https ://doi.org/10.1038/nrend o.2017.36
Jurisicova A, Taniuchi A, Li H, Shang Y, Antenos M, Detmar J, Xu J, 
Matikainen T, Benito Hernández A, Nunez G, Casper RF (2007) 
Maternal exposure to polycyclic aromatic hydrocarbons dimin-
ishes murine ovarian reserve via induction of Harakiri. J Clin 
Invest 117:3971–3978. https ://doi.org/10.1172/JCI28 493
Jørgensen A, Nielsen JE, Blomberg Jensen M, Græm N, Rajpert-De 
Meyts E (2012) Analysis of meiosis regulators in human gonads: 
a sexually dimorphic spatio-temporal expression pattern suggests 
involvement of DMRT1 in meiotic entry. Mol Hum Reprod 
18:523–534. https ://doi.org/10.1093/moleh r/gas03 0
Kawamura K, Kumagai J, Sudo S, Chun SY, Pisarska M, Morita H, 
Toppari J, Fu P, Wade JD, Bathgate RA, Hsueh AJ (2004) Parac-
rine regulation of mammalian oocyte maturation and male germ 
cell survival. Proc Natl Acad Sci USA 101:7323–7328. https ://
doi.org/10.1073/pnas.03070 61101 
Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H (2002) 
Endometriosis: the pathophysiology as an estrogen-dependent 
disease. J Steroid Biochem Mol Biol 83:149–155. https ://doi.
org/10.1016/s0960 -0760(02)00260 -1
Kortenkamp A, Faust M (2010) Combined exposures to anti-androgenic 
chemicals: steps towards cumulative risk assessment. Int J Androl 
33:463–474. https ://doi.org/10.1111/j.1365-2605.2009.01047 .x
Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC 
(2006) Retinoic acid regulates sex-specific timing of meiotic ini-
tiation in mice. Proc Natl Acad Sci USA 103:2474–2479. https 
://doi.org/10.1073/pnas.05108 13103 
Krewski D, Acosta DJ, Andersen M, Anderson H, Bailar JC, Boekel-
heide K, Brent R, Charnley G, Cheung VG, Green SJ, Kelsey 
KT, Kerkvliet NI, Li AA, McCray L, Meyer O, Patterson RD, 
Pennie W, Scala RA, Solomon GM, Stephens M, Yager J, Zeise 
L (2010) Toxicity testing in the 21st century: a vision and a 
strategy. J Toxicol Environ Health B Crit Rev 13:51–138. https 
://doi.org/10.1080/10937 404.2010.48317 6
Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE (2002) The 
specific role of isoflavones on estrogen metabolism in 
3376 Archives of Toxicology (2020) 94:3359–3379
1 3
premenopausal women. Cancer 94:1166–1174. https ://doi.
org/10.1002/cncr.10320 
Lagergren K, Hammar M, Nedstrand E, Bladh M, Sydsjö G (2018) 
The prevalence of primary ovarian insufficiency in Sweden; a 
national register study. BMC Womens Health 18:175. https ://
doi.org/10.1186/s1290 5-018-0665-2
Laier P, Cederberg T, Larsen JC, Vinggaard AM (2003) Applicability 
of the CALUX bioassay for screening of dioxin levels in human 
milk samples. Food Addit Contam 20:583–595. https ://doi.
org/10.1080/02652 03031 00010 7820
Laisk T, Tšuiko O, Jatsenko T, Hõrak P, Otala M, Lahdenperä M, 
Lummaa V, Tuuri T, Salumets A, Tapanainen JS (2019) Demo-
graphic and evolutionary trends in ovarian function and aging. 
Hum Reprod Update 25:34–50. https ://doi.org/10.1093/humup 
d/dmy03 1
Lawson C, Gieske M, Murdoch B, Ye P, Li Y, Hassold T, Hunt PA 
(2011) Gene expression in the fetal mouse ovary is altered by 
exposure to low doses of bisphenol A. Biol Reprod 84:79–86. 
https ://doi.org/10.1095/biolr eprod .110.08481 4
Le Bouffant R, Guerquin MJ, Duquenne C, Frydman N, Coffigny H, 
Rouiller-Fabre V, Frydman R, Habert R, Livera G (2010) Meio-
sis initiation in the human ovary requires intrinsic retinoic acid 
synthesis. Hum Reprod 25:2579–2590. https ://doi.org/10.1093/
humre p/deq19 5
Lebbe M, Taylor AE, Visser JA, Kirkman-Brown JC, Woodruff TK, 
Arlt W (2017) The steroid metabolome in the isolated ovarian 
follicle and its response to androgen exposure and antagonism. 
Endocrinology 158:1474–1485
Lebbe M, Woodruff TK (2013) Involvement of androgens in ovarian 
health and disease. Mol Hum Reprod 19:828–837. https ://doi.
org/10.1093/moleh r/gat06 5
Lefèvre PLC, Berger RG, Ernest SR, Gaertner DW, Rawn DFK, Wade 
MG, Robaire B, Hales BF (2016) Exposure of female rats to an 
environmentally relevant mixture of brominated flame retardants 
targets the ovary, affecting folliculogenesis and steroidogenesis. 
Biol Reprod 94:9. https ://doi.org/10.1095/biolr eprod .115.13445 2
Li H, Clagett-Dame M (2009) Vitamin A deficiency blocks the initia-
tion of meiosis of germ cells in the developing rat ovary in vivo. 
Biol Reprod 81:996–1001. https ://doi.org/10.1095/biolr eprod 
.109.07880 8
Li YR, Ren CE, Zhang Q, Li JC, Chian RC (2013) Expression of G pro-
tein estrogen receptor (GPER) on membrane of mouse oocytes 
during maturation. J Assist Reprod Genet 30:227–232. https ://
doi.org/10.1007/s1081 5-013-9942-z
López-Rodríguez D, Franssen D, Sevrin E, Gérard A, Balsat C, Blacher 
S, Noël A, Parent AS (2019) Persistent vs transient alteration of 
folliculogenesis and estrous cycle after neonatal vs adult expo-
sure to bisphenol A. Endocrinology 160:2558–2572. https ://doi.
org/10.1210/en.2019-00505 
Lutterodt MC, Sørensen KP, Larsen KB, Skouby SO, Andersen CY, 
Byskov AG (2009) The number of oogonia and somatic cells in 
the human female embryo and fetus in relation to whether or not 
exposed to maternal cigarette smoking. Hum Reprod 24:2558–
2566. https ://doi.org/10.1093/humre p/dep22 6
Mamsen LS, Lutterodt MC, Andersen EW, Skouby SO, Sørensen KP, 
Andersen CY, Byskov AG (2010) Cigarette smoking during early 
pregnancy reduces the number of embryonic germ and somatic 
cells. Hum Reprod 25:2755–2761. https ://doi.org/10.1093/humre 
p/deq21 5
Marti N, Galván JA, Pandey AV, Trippel M, Tapia C, Müller M, Per-
ren A, Flück CE (2017) Genes and proteins of the alternative 
steroid backdoor pathway for dihydrotestosterone synthesis are 
expressed in the human ovary and seem enhanced in the poly-
cystic ovary syndrome. Mol Cell Endocrinol 441:116–123. https 
://doi.org/10.1016/j.mce.2016.07.029
Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens 
GA (2012) National, regional, and global trends in infertil-
ity prevalence since 1990: a systematic analysis of 277 health 
surveys. PLoS Med 9:e1001356. https ://doi.org/10.1371/journ 
al.pmed.10013 56
Matikainen T, Perez GI, Jurisicova A, Pru JK, Schlezinger JJ, Ryu HY, 
Laine J, Sakai T, Korsmeyer SJ, Casper RF, Sherr DH, Tilly JL 
(2001) Aromatic hydrocarbon receptor-driven Bax gene expres-
sion is required for premature ovarian failure caused by biohaz-
ardous environmental chemicals. Nat Genet 28:355–360. https 
://doi.org/10.1038/ng575 
Matikainen TM, Moriyama T, Morita Y, Perez GI, Korsmeyer SJ, 
Sherr DH, Tilly JL (2002) Ligand activation of the aromatic 
hydrocarbon receptor transcription factor drives Bax-dependent 
apoptosis in developing fetal ovarian germ cells. Endocrinology 
143:615–620. https ://doi.org/10.1210/endo.143.2.8624
Mazaud S, Guigon CJ, Lozach A, Goudouel N, Forest MG, Coffigny H, 
Magre S (2002) Establishment of the reproductive function and 
transient fertility of female rats lacking primordial follicle stock 
after fetal gamma-irradiation. Endocrinology 143:4775–4787. 
https ://doi.org/10.1210/en.2002-22046 4
McLaren A, Southee D (1997) Entry of mouse embryonic germ cells 
into meiosis. Dev Biol 187:107–113. https ://doi.org/10.1006/
dbio.1997.8584
Migliaccio M, Chioccarelli T, Ambrosino C, Suglia A, Manfrevola F, 
Carnevali O, Fasano S, Pierantoni R, Cobellis G (2018) Charac-
terization of follicular atresia responsive to BPA in zebrafish by 
morphometric analysis of follicular stage progression. Int J Endo-
crinol 2018:4298195. https ://doi.org/10.1155/2018/42981 95
Missmer SA, Hankinson SE, Spiegelman D, Barbieri RL, Michels KB, 
Hunter DJ (2004) In utero exposures and the incidence of endo-
metriosis. Fertil Steril 82:1501–1508. https ://doi.org/10.1016/j.
fertn stert .2004.04.065
Moenter SM, Silveira MA, Wang L, Adams C (2020) Central aspects 
of systemic estradiol negative and positive feedback on the repro-
ductive neuroendocrine system. J Neuroendocrinol 32:e12724. 
https ://doi.org/10.1111/jne.12724 
Neal MS, Mulligan Tuttle AM, Casper RF, Lagunov A, Foster WG 
(2010) Aryl hydrocarbon receptor antagonists attenuate the 
deleterious effects of benzo[a]pyrene on isolated rat follicle 
development. Reprod Biomed Online 21:100–108. https ://doi.
org/10.1016/j.rbmo.2010.03.025
Nef S, Parada LF (1999) Cryptorchidism in mice mutant for Insl3. Nat 
Genet 22:295–299. https ://doi.org/10.1038/10364 
Nelson LM (2009) Clinical practice. Primary ovarian insufficiency. N 
Engl J Med 360:606–614. https ://doi.org/10.1056/NEJMc p0808 
697
Nepelska M, Grignard E, Munn S (2016) AOP7: aromatase (Cyp19a1) 
reduction leading to impaired fertility in adult female. In: AOP-
wiki, vol 2019. https ://aopwi ki.org/aops/7
OECD (2011) Test No. 456: H295R steroidogenesis assay. OECD 
guidelines for the Testing of Chemicals, Section 4. OECD Pub-
lishing, Paris. https ://doi.org/10.1787/97892 64122 642-en
OECD (2016a) Test no. 455: performance-based test guideline for sta-
bly transfected transactivation in vitro assays to detect estrogen 
receptor agonists and antagonists. OECD Guidelines for the Test-
ing of Chemicals, Section 4. OECD Publishing, Paris. https ://doi.
org/10.1787/97892 64265 295-en
OECD (2016b) Test no. 458: stably transfected human androgen recep-
tor transcriptional activation assay for detection of androgenic 
agonist and antagonist activity of chemicals. OECD Guidelines 
for the Testing of Chemicals, Section 4. OECD Publishing. https 
://doi.org/10.1787/97892 64264 366-en
OECD (2017) Revised guidance document on developing and assessing 
adverse outcome pathways, GD 184. OECD Publishing, Paris. 
3377Archives of Toxicology (2020) 94:3359–3379 
1 3
https ://www.oecd.org/offic ialdo cumen ts/publi cdisp laydo cumen 
tpdf/?cote=env/jm/mono(2013)6&docla nguag e=en
OECD (2018a) Revised guidance document 150 on standardised test 
guidelines for evaluating chemicals for endocrine disruption. 
OECD Series on Testing and Assessment, No 150. OECD Pub-
lishing, Paris. https ://doi.org/10.1787/97892 64304 741-en
OECD (2018b) User’s handbook supplement to the guidance document 
for developing and assessing AOPs. OECD Publishing ENV/
JM/MONO(2016)12. https ://doi.org/10.1787/5jlv1 m9d1g 32-en
Palioura E, Diamanti-Kandarakis E (2015) Polycystic ovary syn-
drome (PCOS) and endocrine disrupting chemicals (EDCs). 
Rev Endocr Metab Disord 16:365–371. https ://doi.org/10.1007/
s1115 4-016-9326-7
Palmer JR, Hatch EE, Rao RS, Kaufman RH, Herbst AL, Noller KL, 
Titus-Ernstoff L, Hoover RN (2001) Infertility among women 
exposed prenatally to diethylstilbestrol. Am J Epidemiol 
154:316–321. https ://doi.org/10.1093/aje/154.4.316
Pang Y, Thomas P (2018) Role of natriuretic peptide receptor 
2-mediated signaling in meiotic arrest of zebrafish oocytes 
and its estrogen regulation through G protein-coupled estro-
gen receptor (Gper). Gen Comp Endocrinol. https ://doi.
org/10.1016/j.ygcen .2018.03.024
Patel S, Brehm E, Gao L, Rattan S, Ziv-Gal A, Flaws JA (2017) 
Bisphenol A exposure, ovarian follicle numbers, and female 
sex steroid hormone levels: results from a CLARITY-BPA 
study. Endocrinology 158:1727–1738. https ://doi.org/10.1210/
en.2016-1887
Pepling ME (2006) From primordial germ cell to primordial follicle: 
mammalian female germ cell development. Genesis 44:622–632. 
https ://doi.org/10.1002/dvg.20258 
Pepling ME, Sundman EA, Patterson NL, Gephardt GW, Medico LJ, 
Wilson KI (2010) Differences in oocyte development and estra-
diol sensitivity among mouse strains. Reproduction 139:349–
357. https ://doi.org/10.1530/REP-09-0392
Peyton C, Thomas P (2011) Involvement of epidermal growth factor 
receptor signaling in estrogen inhibition of oocyte maturation 
mediated through the G protein-coupled estrogen receptor (Gper) 
in zebrafish (Danio rerio). Biol Reprod 85:42–50. https ://doi.
org/10.1095/biolr eprod .110.08876 5
Pizzorno J (2018) Environmental toxins and infertility. Integr Med 
(Encinitas) 17:8–11
Ploteau S, Cano-Sancho G, Volteau C, Legrand A, Vénisseau A, Vacher 
V, Marchand P, Le Bizec B, Antignac JP (2017) Associations 
between internal exposure levels of persistent organic pollutants 
in adipose tissue and deep infiltrating endometriosis with or with-
out concurrent ovarian endometrioma. Environ Int 108:195–203. 
https ://doi.org/10.1016/j.envin t.2017.08.019
Prescott J, Farland LV, Tobias DK, Gaskins AJ, Spiegelman D, 
Chavarro JE, Rich-Edwards JW, Barbieri RL, Missmer SA 
(2016) A prospective cohort study of endometriosis and subse-
quent risk of infertility. Hum Reprod 31:1475–1482. https ://doi.
org/10.1093/humre p/dew08 5
Pru JK, Kaneko-Tarui T, Jurisicova A, Kashiwagi A, Selesniemi K, 
Tilly JL (2009) Induction of proapoptotic gene expression and 
recruitment of p53 herald ovarian follicle loss caused by polycy-
clic aromatic hydrocarbons. Reprod Sci 16:347–356. https ://doi.
org/10.1177/19337 19108 32759 6
Rad M, Hümpel M, Schaefer O, Schoemaker RC, Schleuning WD, 
Cohen AF, Burggraaf J (2006) Pharmacokinetics and systemic 
endocrine effects of the phyto-estrogen 8-prenylnaringenin after 
single oral doses to postmenopausal women. Br J Clin Pharmacol 
62:288–296. https ://doi.org/10.1111/j.1365-2125.2006.02656 .x
Rasmussen LM, Sen N, Liu X, Craig ZR (2017) Effects of oral expo-
sure to the phthalate substitute acetyl tributyl citrate on female 
reproduction in mice. J Appl Toxicol 37:668–675. https ://doi.
org/10.1002/jat.3413
Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, 
Du C, Tang W, Hämäläinen T, Peng SL, Lan ZJ, Cooney AJ, 
Huhtaniemi I, Liu K (2008) Oocyte-specific deletion of Pten 
causes premature activation of the primordial follicle pool. Sci-
ence 319:611–613. https ://doi.org/10.1126/scien ce.11522 57
Reed CE, Fenton SE (2013) Exposure to diethylstilbestrol during sensi-
tive life stages: a legacy of heritable health effects. Birth Defects 
Res C Embryo Today 99:134–146. https ://doi.org/10.1002/
bdrc.21035 
Roelofs MJ, Piersma AH, van den Berg M, van Duursen MB (2013) 
The relevance of chemical interactions with CYP17 enzyme 
activity: assessment using a novel in  vitro assay. Toxicol 
Appl Pharmacol 268:309–317. https ://doi.org/10.1016/j.
taap.2013.01.033
Ryan KJ, Petro Z, Kaiser J (1968) Steroid formation by isolated and 
recombined ovarian granulosa and tehcal cells. J Clin Endocrinol 
Metab 28:355–358. https ://doi.org/10.1210/jcem-28-3-355
Sagvekar P, Kumar P, Mangoli V, Desai S, Mukherjee S (2019) DNA 
methylome profiling of granulosa cells reveals altered methyla-
tion in genes regulating vital ovarian functions in polycystic 
ovary syndrome. Clin Epigenet 11:61. https ://doi.org/10.1186/
s1314 8-019-0657-6
Santangeli S, Maradonna F, Gioacchini G, Cobellis G, Piccinetti CC, 
Dalla Valle L, Carnevali O (2016) BPA-induced deregulation of 
epigenetic patterns: effects on female zebrafish reproduction. Sci 
Rep 6:21982. https ://doi.org/10.1038/srep2 1982
Schwartz CL, Christiansen S, Vinggaard AM, Axelstad M, Hass U, 
Svingen T (2019) Anogenital distance as a toxicological or clini-
cal marker for fetal androgen action and risk for reproductive 
disorders. Arch Toxicol 93:253–272. https ://doi.org/10.1007/
s0020 4-018-2350-5
Scully MM, Palacios-Helgeson LK, Wah LS, Jackson TA (2014) Rapid 
estrogen signaling negatively regulates PTEN activity through 
phosphorylation in endometrial cancer cells. Horm Cancer 
5:218–231. https ://doi.org/10.1007/s1267 2-014-0184-z
Sen A, Caiazza F (2013) Oocyte maturation: a story of arrest and 
release. Front Biosci (Schol Ed) 5:451–477. https ://doi.
org/10.2741/s383
Sheng ZG, Zhu BZ (2011) Low concentrations of bisphenol A induce 
mouse spermatogonial cell proliferation by G protein-coupled 
receptor 30 and estrogen receptor-α. Environ Health Perspect 
119:1775–1780. https ://doi.org/10.1289/ehp.11037 81
Small CM, Manatunga AK, Klein M, Feigelson HS, Dominguez CE, 
McChesney R, Marcus M (2006) Menstrual cycle characteristics: 
associations with fertility and spontaneous abortion. Epidemiol-
ogy 17:52–60. https ://doi.org/10.1097/01.ede.00001 90540 .95748 
.e6
Spanel-Borowski K, Schäfer I, Zimmermann S, Engel W, Adham IM 
(2001) Increase in final stages of follicular atresia and prema-
ture decay of corpora lutea in Insl3-deficient mice. Mol Reprod 
Dev 58:281–286. https ://doi.org/10.1002/1098-2795(20010 
3)58:3<281:AID-MRD6>3.0.CO;2-0
Spiller C, Koopman P, Bowles J (2017) Sex determination in the 
mammalian germline. Annu Rev Genet 51:265–285. https ://doi.
org/10.1146/annur ev-genet -12021 5-03544 9
Susiarjo M, Hassold TJ, Freeman E, Hunt PA (2007) Bisphenol A 
exposure in utero disrupts early oogenesis in the mouse. PLoS 
Genet 3:e5. https ://doi.org/10.1371/journ al.pgen.00300 05
Tarnow P, Tralau T, Luch A (2019) Chemical activation of estrogen 
and aryl hydrocarbon receptor signaling pathways and their 
interaction in toxicology and metabolism. Expert Opin Drug 
Metab Toxicol 15:219–229. https ://doi.org/10.1080/17425 
255.2019.15696 27
Thomas P, Dong J (2006) Binding and activation of the seven-trans-
membrane estrogen receptor GPR30 by environmental estrogens: 
a potential novel mechanism of endocrine disruption. J Steroid 
3378 Archives of Toxicology (2020) 94:3359–3379
1 3
Biochem Mol Biol 102:175–179. https ://doi.org/10.1016/j.jsbmb 
.2006.09.017
Torrealday S, Kodaman P, Pal L (2017) Premature ovarian insuffi-
ciency—an update on recent advances in understanding and 
management. F1000Res 6:269. https ://doi.org/10.12688 /f1000 
resea rch.11948 .1
Tuttle AM, Stämpfli M, Foster WG (2009) Cigarette smoke causes 
follicle loss in mice ovaries at concentrations representative 
of human exposure. Hum Reprod 24:1452–1459. https ://doi.
org/10.1093/humre p/dep02 3
Upson K, De Roos AJ, Thompson ML, Sathyanarayana S, Scholes D, 
Barr DB, Holt VL (2013) Organochlorine pesticides and risk 
of endometriosis: findings from a population-based case-con-
trol study. Environ Health Perspect 121:1319–1324. https ://doi.
org/10.1289/ehp.13066 48
Vabre P, Gatimel N, Moreau J, Gayrard V, Picard-Hagen N, Parinaud J, 
Leandri RD (2017) Environmental pollutants, a possible etiology 
for premature ovarian insufficiency: a narrative review of animal 
and human data. Environ Health 16:37. https ://doi.org/10.1186/
s1294 0-017-0242-4
Vagi SJ, Azziz-Baumgartner E, Sjödin A, Calafat AM, Dumesic D, 
Gonzales L, Kato K, Silva MJ, Ye X, Azziz R (2014) Exploring 
the potential association between brominated diphenyl ethers, 
polychlorinated biphenyls, organochlorine pesticides, perfluori-
nated compounds, phthalates, and bisphenol A in polycystic 
ovary syndrome: a case-control study. BMC Endocr Disord 
14:86. https ://doi.org/10.1186/1472-6823-14-86
van de Lisdonk E, van den Bosch W, Lagro-Janssen A (2008) Ziekten 
in de huisartsenpraktijk. Elsevier Gezondheidszorg
van Duursen MBM, Boberg J, Christiansen S, Connolly L, Damdi-
mopoulou P, Filis P, Fowler PA, Gadella BM, Holte J, Jääger K, 
Johansson HK, Li T, Mazaud-Guittot S, Parent AS, Salumets A, 
Soto AM, Svingen T, Velthut-Meikas A, Wedebye EB, Xie Y, 
Van den Berg M (2020) Safeguarding female reproductive health 
against endocrine disrupting chemicals—the FREIA project. Int J 
Mol Sci 21:E3215. https ://doi.org/10.3390/ijms2 10932 15
Vander Borght M, Wyns C (2018) Fertility and infertility: defini-
tion and epidemiology. Clin Biochem 62:2–10. https ://doi.
org/10.1016/j.clinb ioche m.2018.03.012
Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA 
(1999) Androgens promote oocyte insulin-like growth factor I 
expression and initiation of follicle development in the primate 
ovary. Biol Reprod 61:353–357. https ://doi.org/10.1095/biolr 
eprod 61.2.353
Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA (1998) Andro-
gens stimulate early stages of follicular growth in the primate 
ovary. J Clin Invest 101:2622–2629. https ://doi.org/10.1172/
JCI20 81
Vercellini P, Viganò P, Somigliana E, Fedele L (2014) Endometriosis: 
pathogenesis and treatment. Nat Rev Endocrinol 10:261–275. 
https ://doi.org/10.1038/nrend o.2013.255
Viguié C, Mhaouty-Kodja S, Habert R, Chevrier C, Michel C, Pasquier 
E (2018) Evidence-based adverse outcome pathway approach for 
the identification of BPA as en endocrine disruptor in relation to 
its effect on the estrous cycle. Mol Cell Endocrinol 475:10–28. 
https ://doi.org/10.1016/j.mce.2018.02.007
Vinggaard AM, Niemelä J, Wedebye EB, Jensen GE (2008) Screening 
of 397 chemicals and development of a quantitative structure–
activity relationship model for androgen receptor antagonism. 
Chem Res Toxicol 21:813–823. https ://doi.org/10.1021/tx700 
2382
Visser JA, De Jong FH, Laven JS, Themmen AP (2006) Anti-Mülle-
rian hormone: a new marker for ovarian function. Reproduction 
131:1–9. https ://doi.org/10.1530/rep.1.00529 
Vom Saal FS, Hughes C (2005) An extensive new literature concerning 
low-dose effects of bisphenol A shows the need for a new risk 
assessment. Environ Health Perspect 113:926–933. https ://doi.
org/10.1289/ehp.7713
Wallace WH, Kelsey TW (2010) Human ovarian reserve from con-
ception to the menopause. PLoS ONE 5:e8772. https ://doi.
org/10.1371/journ al.pone.00087 72
Wang C, Prossnitz ER, Roy SK (2008) G protein-coupled receptor 30 
expression is required for estrogen stimulation of primordial fol-
licle formation in the hamster ovary. Endocrinology 149:4452–
4461. https ://doi.org/10.1210/en.2008-0441
Wang Y, Ni C, Li X, Lin Z, Zhu Q, Li L, Ge RS (2019) Phthalate-
induced fetal leydig cell dysfunction mediates male reproduc-
tive tract anomalies. Front Pharmacol 10:1309. https ://doi.
org/10.3389/fphar .2019.01309 
Wang Z, Walker GW, Muir DCG, Nagatani-Yoshida K (2020) Toward 
a global understanding of chemical pollution: a first compre-
hensive analysis of national and regional chemical inventories. 
Environ Sci Technol 54:2575–2584. https ://doi.org/10.1021/acs.
est.9b063 79
Wato E, Asahiyama M, Suzuki A, Funya S, Amano Y (2009) Col-
laborative work on evaluation of ovarian toxicity. 9) Effects of 
2- or 4-week repeated dose studies and fertility study of di(2-eth-
ylhexyl)adipate (DEHA) in female rats. J Toxicol Sci 34(Suppl 
1):101–109. https ://doi.org/10.2131/jts.34.s101
Wu XJ, Thomas P, Zhu Y (2018) Pgrmc1 knockout impairs oocyte 
maturation in zebrafish. Front Endocrinol (Lausanne) 9:560. 
https ://doi.org/10.3389/fendo .2018.00560 
Xue K, Kim JY, Liu JY, Tsang BK (2014) Insulin-like 3-induced rat 
preantral follicular growth is mediated by growth differentiation 
factor 9. Endocrinology 155:156–167. https ://doi.org/10.1210/
en.2013-1491
Yang JL, Zhang CP, Li L, Huang L, Ji SY, Lu CL, Fan CH, Cai H, Ren 
Y, Hu ZY, Gao F, Liu YX (2010) Testosterone induces redistri-
bution of forkhead box-3a and down-regulation of growth and 
differentiation factor 9 messenger ribonucleic acid expression at 
early stage of mouse folliculogenesis. Endocrinology 151:774–
782. https ://doi.org/10.1210/en.2009-0751
Ye X, Skjaerven R, Basso O, Baird DD, Eggesbo M, Cupul Uicab LA, 
Haug K, Longnecker MP (2010) In utero exposure to tobacco 
smoke and subsequent reduced fertility in females. Hum Reprod 
25:2901–2906. https ://doi.org/10.1093/humre p/deq23 5
Yuan L, Liu JG, Hoja MR, Wilbertz J, Nordqvist K, Höög C (2002) 
Female germ cell aneuploidy and embryo death in mice lacking 
the meiosis-specific protein SCP3. Science 296:1115–1118. https 
://doi.org/10.1126/scien ce.10705 94
Zhang S, Tan R, Pan R, Xiong J, Tian Y, Wu J, Chen L (2018) Associa-
tion of perfluoroalkyl and polyfluoroalkyl substances with prema-
ture ovarian insufficiency in Chinese women. J Clin Endocrinol 
Metab 103:2543–2551. https ://doi.org/10.1210/jc.2017-02783 
Zhang XF, Zhang T, Han Z, Liu JC, Liu YP, Ma JY, Li L, Shen W 
(2015) Transgenerational inheritance of ovarian development 
deficiency induced by maternal diethylhexyl phthalate expo-
sure. Reprod Fertil Dev 27:1213–1221. https ://doi.org/10.1071/
RD141 13
Zhang Y, Ji L, Hu Y, Tse LA, Wang Y, Qin K, Ding G, Zhou Y, Yu X, 
Ouyang F, Zhang J, Gao Y, Tian Y, Study SBC (2019) Organo-
phosphate pesticide exposures and menstrual cycle characteris-
tics in Chinese preconception women. Am J Epidemiol. https ://
doi.org/10.1093/aje/kwz24 2
Zheng W, Zhang H, Gorre N, Risal S, Shen Y, Liu K (2014) Two 
classes of ovarian primordial follicles exhibit distinct develop-
mental dynamics and physiological functions. Hum Mol Genet 
23:920–928. https ://doi.org/10.1093/hmg/ddt48 6
Zhu JQ, Zhu L, Liang XW, Xing FQ, Schatten H, Sun QY (2010) 
Demethylation of LHR in dehydroepiandrosterone-induced 
mouse model of polycystic ovary syndrome. Mol Hum Reprod 
16:260–266. https ://doi.org/10.1093/moleh r/gap08 9
3379Archives of Toxicology (2020) 94:3359–3379 
1 3
Zickler D, Kleckner N (2015) Recombination, pairing, and synapsis 
of homologs during meiosis. Cold Spring Harb Perspect Biol 
7:a016626. https ://doi.org/10.1101/cshpe rspec t.a0166 26
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Hanna K. L. Johansson1  · Pauliina Damdimopoulou2  · Majorie B. M. van Duursen3  · Julie Boberg1  · 
Delphine Franssen4  · Marijke de Cock5  · Kersti Jääger6  · Magdalena Wagner2  · Agne Velthut‑Meikas6,7  · 
Yuling Xie8 · Lisa Connolly8  · Pauline Lelandais9 · Severine Mazaud‑Guittot9  · Andres Salumets6,10,11  · 
Monica Kam Draskau1  · Panagiotis Filis12  · Paul A. Fowler12  · Sofie Christiansen1  · Anne‑Simone Parent4,13  · 
Terje Svingen1 
1 Division of Diet, Disease Prevention and Toxicology, 
National Food Institute, Technical University of Denmark, 
2800 Kongens Lyngby, Denmark
2 Department of Clinical Science, Intervention 
and Technology, Karolinska Institutet and Karolinska 
University Hospital, 14186 Stockholm, Sweden
3 Department Environment and Health, Vrije Universiteit 
Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, 
The Netherlands
4 Neuroendocrinology Unit, GIGA Neurosciences, University 
of Liège, Sart-Tilman, 4000 Liège, Belgium
5 Faculty of Science, Vrije Universiteit Amsterdam, 
1081 HV Amsterdam, The Netherlands
6 Competence Centre on Health Technologies, Tartu, Estonia
7 Department of Chemistry and Biotechnology, School 
of Science, Tallinn University of Technology, Tallinn, 
Estonia
8 Institute for Global Food Security, School of Biological 
Sciences, Queen’s University Belfast, Belfast BT9 5DL, 
Northern Ireland, UK
9 Inserm, EHESP, Irset (Institut de Recherche en Santé, 
Environnement et Travail) UMR_S 1085, University Rennes, 
35000 Rennes, France
10 Department of Obstetrics and Gynaecology, Institute 
of Clinical Medicine, University of Tartu, Tartu, Estonia
11 Department of Obstetrics and Gynecology, University 
of Helsinki, Helsinki University Hospital, Helsinki, Finland
12 Institute of Medical Sciences, University of Aberdeen, 
Foresterhill, Aberdeen AB25 2ZD, UK
13 Department of Pediatrics, CHU de Liège, Rue de 
Gaillarmont 600, 4032 Liège, Belgium
